Metabolism of Thyroid Hormone

Last Updated:




Thyroid hormone is indispensable for normal development and metabolism of most cells and tissues. Thyroid hormones are metabolized by different pathways: glucuronidation, sulfation, and deiodination, the latter being the most important. Three enzymes catalyzing deiodination have been identified, called type 1 (D1), type 2 (D2) and type 3 (D3) iodothyronine deiodinases. D1 and D2 have outer ring deiodinase activity, converting the prohormone T4 to its bioactive form T3 and degrading rT3 to 3,3’-T2. D3 has inner ring deiodinase activity and degrades T4 to rT3 and T3 to 3,3’-T2.

D1 is largely expressed in liver and kidney. Its main role is clearance of rT3 from the circulation and it also contributes to production of plasma T3. D2 is importantly expressed in the central nervous system, pituitary, brown adipose tissue and muscle and, generally, its expression reciprocally responds to changes in thyroid state. D2 serves to adapt cellular thyroid state to changing physiological needs. D3 is importantly expressed in fetal tissues and in adult brain tissue. In addition, D3 can be re-expressed under certain pathological conditions such as critical illness or in specific cancers.

In recent years, the paradigm has evolved that D2 and D3 can locally modify thyroid hormone bioactivity independent of serum thyroid hormone concentrations. Its physiological relevance has been shown in various developmental and regenerative conditions. Future studies may reveal if modifying (local) deiodinase activity can be of use under certain circumstances. For complete coverage of all related areas of Endocrinology, please see our online FREE web-book, and WWW.THYROIDMANAGER.ORG.





In healthy humans the thyroid gland produces predominantly the prohormone T4 together with a small amount of the bioactive hormone T3. Most T3 is produced by enzymatic outer ring deiodination (ORD) of T4 in peripheral tissues. Alternative, inner ring deiodination (IRD) of T4 yields the metabolite rT3, the thyroidal secretion of which is negligible. Normally, about one-third of T4 is converted to T3 and about one-third to rT3. The remainder of T4 is metabolized by different pathways, in particular glucuronidation and sulfation. T3 is further metabolized largely by IRD and rT3 largely by ORD, yielding in both cases the metabolite 3,3’T2. Thus, ORD is regarded as an activating pathway and IRD as an inactivating pathway.

Three enzymes catalyzing these deiodinations have been identified, called type 1 (D1), type 2 (D2) and type 3 (D3) iodothyronine deiodinases. All three deiodinases have been cloned and characterized in a variety of species. Together, they form a family of homologous selenoproteins which consist of »250-280 amino acids, including an essential selenocysteine residue in the active center. It is remarkable, therefore, that production and metabolism of thyroid hormone are dependent on two trace elements, namely iodine and selenium.

D1 is expressed mainly in the liver, the kidneys and the thyroid. In particular the hepatic enzyme is thought to contribute importantly to peripheral T3 production and to be the main site for the clearance of plasma rT3. These processes are mediated by the ORD activity of D1. However, D1 also has IRD activity, especially towards sulfated T4 and T3. Therefore, in addition to the bioactivation of T4 to T3, D1 also catalyzes the degradation of thyroid hormone. An important property distinguishing D1 from the other deiodinases is its sensitivity to inhibition by the anti-thyroid drug propylthiouracil (PTU). The important role of D1 in the peripheral production of plasma T3 has been demonstrated by the marked decrease in plasma T3 levels in T4-substituted athyreotic subjects treated with PTU.

D2 has been studied extensively in the central nervous system, the pituitary, brown adipose tissue and skeletal muscle of experimental animals. D2 has only ORD activity and its expression shows adaptive changes in response to alterations in thyroid state, which serves to maintain tissue T3 levels in the face of varying plasma T4 and T3 levels. Cell-specific modulation of D2 enables to adapt to physiological needs.

D3 mediates the degradation of thyroid hormone since it has only IRD activity. The brain is the predominant D3-expressing tissue in adult animals, and may thus be the main site for the clearance of plasma T3 and for the production of plasma rT3. However, high D3 activities have been demonstrated in the placenta and the pregnant uterus as well as in different fetal tissues. The high D3 activities at these sites appear to prevent exposure of fetal tissues to high T3 levels, allowing the growth of these tissues. T3 is only required at the differentiation stage of tissue development.

Whereas intitial studies focused on the role of the deiodinases in maintaining normal serum T3 concentrations, the paradigm has evolved that these enzymes can locally modify TH bioactivity independent of serum TH concentrations. An example is the critical role of D2 and D3 in cochlear development, since Dio2-/- as well as Dio3-/- mice have severe hearing loss. These enzymes prevent too little or too much hormonal stimulation at inappropriate stages in development. At immature stages, D3 limits stimulation by T3. Postnatally, a double switch occurs with a decline in D3 and an increase D2, resulting in a local T3 surge which is independent of serum T3 levels and triggers the onset of auditory function.

Clinically, the importance of the deiodinases in the regulation of thyroid hormone bioactivity is apparent when their activity is affected by patho-physiological conditions. Examples of such conditions are iodine insufficiency, thyroidal and non-thyroidal illness and malnutrition.

Expression of D1 and D3 is under positive control and that of D2 is under negative control of thyroid hormone. Therefore, the relative contribution of D1 and D2 to peripheral T3 production varies with thyroid state, with D1 prevailing in the hyperthyroid and D2 in the hypothyroid state. The proportions of T3 being produced via D1 or D2 in euthyroid subjects remain to be established.

In iodine deficiency, D1-mediated peripheral T3 production decreases but this is in part compensated by an increased thyroidal T3 production, which is mediated by an increased TSH secretion as well as by increased efficiency of D2-mediated T3 production. Simultaneously, neuronal D3 expression decreases thereby prolonging the local half-life of T3.

In non-thyroidal illness (NTI) plasma T3 is often decreased and plasma rT3 increased; plasma FT4 is still in the normal range depending on the severity of disease. The changes in plasma T3 and rT3 are explained by a diminished conversion of T4 to T3 and of rT3 to 3,3-T2 by D1 in the liver. Although this may be caused to some extent by decreased D1 expression or cofactor levels, a diminished activity of transporter(s) mediating hepatic uptake of T4 and rT3 appears to be another important mechanism. This also holds for the generation of the low T3 syndrome in malnutrition.

In addition to a decreased peripheral T3 production, the low T3 syndrome of NTI may also be caused by stimulated thyroid hormone degradation due to induction of D3 in different tissues. Pathological expression of D3 may be so high that this results in a state of consumptive hypothyroidism with low serum (F)T4 and T3 and very high rT3 levels. This has been shown in different patients with hemangiomas which express very high D3 activities.

Finally, peripheral production of T3 can be inhibited by a variety of drugs, including PTU, dexamethasone, propranolol, and iodinated compounds such as the radiographic agents iopanoic acid and ipodate and the anti-arrhythmic drug amiodarone. PTU is a specific uncompetitive inhibitor of D1, while iopanoic acid and ipodate are competitive inhibitors not only of D1 but also of D2. In addition, the radiographic agents inhibit hepatic uptake of thyroid hormone. Amiodarone and its metabolite desethylamidarone may also interfere with peripheral thyroid hormone levels by inhibition of deiodinase activities and tissue thyroid hormone transport. Little is known about the mechanisms by which propranolol and dexamethasone inhibit peripheral T3 production. Combinations of these drugs (e.g. PTU, ipodate, dexamethasone and/or propranolol) may be used to acutely decrease plasma T3 levels in patients with severe hyperthyroidism (toxic storm).

Thyroid hormone metabolism in humans

In healthy human subjects with an adequate iodine intake, the thyroid gland produces predominantly the prohormone T4 and a small amount of the bioactive thyroid hormone T3. Roughly 80% of T3 is produced by outer ring deiodination (ORD) of T4 in peripheral tissues. The relative contribution of T3 secretion increases in iodine deficiency and other conditions where the thyroid gland is stimulated by TSH or TSH receptor antibodies, since this is associated with increased de novo T3 synthesis and thyroidal expression of both D1 and D2, and thus increased intra-thyroidal T4 to T3 conversion (see below). Nevertheless, there is good agreement that about 1/3 of T4 daily produced (~130 nmol) in normal humans is converted to T3, which corresponds to about 40 nmol and thus 80% of the estimated total daily T3 production of 50 nmol. For recent comprehensive reviews of thyroid hormone metabolism and the role of the iodothyronine deiodinases therein, the reader is referred to (1-5)


That most plasma T3 is derived from peripheral conversion of T4 is supported by the fact that normal plasma T3 levels are obtained in athyreotic patients treated with sufficient T4 to achieve high-normal plasma (F)T4 levels. Administration of T4 to hypothyroid rats to achieve normal plasma T4 levels results in subnormal plasma T3 levels not only because of the lack of T3 secretion but also because of a decreased T3 production by D1 in peripheral tissues, since this enzyme is under positive control of T3 itself (6). Other studies in hypothyroid rats suggest that optimal restoration of serum and tissue thyroid hormone levels is achieved by the combined administration of specific amounts of T4 and T3 (7).

Also initial studies in humans suggested that replacement with a combination of T4 and T3 is better than replacement with T4 alone (8). However, this has not been confirmed in a large number of subsequent studies (reviewed in (9, 10)). A common drawback of these trials testing the possible beneficial effects of adding T3 to the T4 replacement therapy is that regular T3 tablets were used. Due to its short half-life, this results in substantial fluctuations of serum T3 levels. It remains to be investigated if administration of T3 in a slow-release formula which better mimics the continuous thyroidal T3 secretion (11) may improve the outcome of combined T4 and T3 replacement. Furthermore, psychological well-being and preference for L-T4 + L-T3 combination therapy may be influenced by polymorphisms in thyroid hormone pathway genes, specifically in thyroid hormone transporters and deiodinases (12-14).

Besides ORD to T3, T4 is converted by inner ring deiodination (IRD) to the metabolite rT3 (Fig. 1), which accounts for about 40% of T4 turnover, while thyroidal secretion of rT3 is negligible. T3 and rT3 undergo further deiodination, predominantly to the common metabolite 3,3′-diiodothyronine (3,3’T2), which is generated by IRD of T3 and by ORD of rT3 (1-5). Thus, ORD is an activating pathway by which the prohormone T4 is converted to active T3, whereas IRD is an inactivating pathway by which T4 and T3 are converted to the metabolites rT3 and 3,3’T2, respectively.

Figure 1. Pathways of Thyroid Hormone Metabolism


In addition to deiodination, iodothyronines are metabolized by conjugation of the phenolic hydroxyl group with sulfate or glucuronic acid (Fig. 1) (15, 16). Sulfation and glucuronidation are so-called phase II detoxification reactions, the general purpose of which is to increase the water-solubility of the substrates and, thus, to facilitate their biliary and/or urinary clearance. However, iodothyronine sulfate levels are normally very low in plasma, bile and urine, because these conjugates are rapidly degraded by D1, suggesting that sulfate conjugation is a primary step leading to the irreversible inactivation of thyroid hormone (17, 18). Plasma levels and, if investigated, biliary excretion of iodothyronine sulfates are increased by inhibition of D1 activity with PTU or iopanoic acid (IOP), and during fetal development, NTI and fasting (16, 18). Under these conditions, T3 sulfate (T3S) may function as a reservoir of inactive hormone from which active T3 may be recovered by action of tissue sulfatases and bacterial sulfatases in the intestine (15-17).

In contrast to the sulfates, iodothyronine glucuronides are rapidly excreted in the bile. However, this is not an irreversible pathway of hormone disposal. After hydrolysis of the glucuronides by bacterial ß-glucuronidases in the intestines, part of the liberated iodothyronines is reabsorbed, resulting in an enterohepatic cycle of iodothyronines (15, 16). Nevertheless, about 20% of daily T4 production appears in the feces, probably through biliary excretion of glucuronide conjugates.

Thyronamines (TAMs) are a novel class of iodothyronine-like endogenous signaling compounds (19). Their structure differs from T4 and T3 only with regard to the absence of the carboxylate group of the alanine side chain. THs and TAMs are designated Tx and TxAM, respectively, with “x” indicating the number of iodine atoms per molecule, thus following the same rules for nomenclature (see (20) for an excellent review). So far, only 3-iodothyronamine (3-T1AM) and thyronamine (T0AM) have been detected in vivo using liquid chromatography-tandem mass spectrometry (LC-MS/MS) (19, 21). 3T1AM and T0AM have been shown to exert acute and dramatic effects on heart rate, body temperature and physical activity, inducing a torpor-like state (19), but also more subtle effects on neurocognitive function (22). The physiological receptor(s) of TAMs has not been identified unambiguously, but despite their structural similarities, iodothyronines and TAMs appear to signal via different receptors. Initial studies suggested that the TAMs mediated their effects via the G-protein coupled trace amine receptor, TAR1 (19). However, the impressive hypothermic response to 3-T1AM administration is maintained in TAAR-1 knockout (23). Whether other members of the TAAR family or other plasma membrane receptors mediate the TAM response remains to be studied.

Studies in athyreotic patients provide evidence for extrathyroidal formation of 3-T1AM (24), but the pathways of TAM biosynthesis are still unknown (41). However, it has been shown that iodothyronamines are deiodinated by the different deiodinases (25), which may suggest a role in biosynthesis.

Interesting effects of other natural thyroid hormone derivatives have been described as well (26). Triac has significant thyromimetic activity and its affinity for the T3 receptor TRα1 is equal to that of T3 and for the TRβ receptor it is even higher than that of T3 (26). As a consequence, administration of Triac has successfully been used to suppress TSH secretion in patients with resistance to thyroid hormone due to mutations in TRβ (27). Interestingly, it was recently shown that the marine invertebrate Amphioxus expresses a TH receptor which is activated by Triac but not by T3 (28), as well as a non-selenoprotein that deiodinates Triac but not T3 (29). This may suggest that Triac is the primordial TH (29). A different natural TH derivative, 3,5-diiodo-L-thyronine (T2), has been shown to prevent adiposity and body weight gain when administered to rats receiving a high-fat diet (HFD) without the unfavorable side effects that are usually caused by T3 (30, 31).

However, the exact biological functions of these iodothyronine, iodothyronamine and iodothyroacetic acid metabolites remain to be established in future studies.

Cleavage of the ether bond connecting the inner and outer ring of iodothyronines represents a relatively minor pathway of thyroid hormone disposal (16) and will not be discussed here. In the following sections especially the biochemical aspects of the deiodination and conjugation pathways will be reviewed.




Three iodothyronine deiodinases have been identified, with distinct tissue distributions, catalytic specificities, physiological functions, and regulations (Fig. 2) (1-5). Whereas initial studies focused on the role of the deiodinases in maintaining normal serum T3 concentrations, the paradigm has evolved and it has now clearly been shown in different developmental and clinical conditions that these enzymes can locally modify TH bioactivity independent of serum TH concentrations. This is especially the case for D2 and D3 (see below).


Figure 2. Characteristics of the three types iodothyronine deiodinases


D1, D2 and D3 have been cloned in different species, including mammals, frog, chicken and fish. The deduced amino acid sequences of human D1, D2 and D3 are presented in Fig. 3. The deiodinases appear to be homologous proteins, consisting of 249-278 amino acids. A particular lipophilic sequence is present in the N terminal domain of all three deiodinases, which probably represents a membrane-spanning region.


The most remarkable feature of all three iodothyronine deiodinase is that they are selenoproteins, i.e. they contain a selenocysteine (Sec) residue in the center of the amino acid sequence (32). In all selenoproteins, Sec is encoded by a UGA triplet which is an opal stop codon because it usually signals termination of translation. However, if the 3′ untranslated region (3’UTR) of the mRNA contains a particular stem loop structure, termed selenocysteine-insertion sequence (SECIS) element, the UGA codon specifies the insertion of Sec (33, 34). Interestingly, it was recently shown that the marine invertebrate Amphioxus expresses a non-selenoprotein that deiodinates Triac but not T3 (29).



Figure 3. Alignment of the amino acid sequences of human D1, D2 and D3

                U=selenocysteine (Sec)


Type I iodothyronine deiodinase (D1)


D1 is expressed predominantly by liver parenchymal cells, kidney proximal tubular cells, and thyroid follicular cells. Most evidence points to the localization of D1 in the plasma membrane (35). D1 catalyzes the ORD and/or IRD of a variety of iodothyronine derivatives, although it is most effective in catalyzing the ORD of rT3, while the IRD of both T4 and T3 is strongly facilitated by sulfation of these iodothyronines (17). Therefore, although D1 is thought to be a major source of circulating T3, the enzyme shows particularly high activity towards TR-inactive metabolites such as rT3 and the different sulfo-conjugates. This suggests that D1 plays an important role in the recovery of iodide from inactive compounds for reutilization in thyroidal hormone synthesis (36). In the presence of dithiothreitol (DTT) as the cofactor, D1 displays high Km and Vmax values.


Studies of the topography of rat D1 have suggested that the major part of the protein is exposed on the cytoplasmic surface of the membrane (37). Older studies using detergent extracts of rat liver and kidney membranes have suggested that the native enzyme largely exists as a homodimer. This has been confirmed in a number of recent studies utilizing cells transfected with different D1 constructs (2, 38-40). These studies have also demonstrated that amino acids 148-163 constitute the dimerization domain of the D1 protein (DFLVIYIEEAHASDGW in human D1).


The D1 gene is located on human chromosome 1p32-33. It consists of four exons, with exon 1 coding for the 5’UTR and amino acids 1-112, exon 2 for amino acids 113-160, exon 3 for amino acids 161-227, and exon 4 for amino acids 228-249 and the 3’UTR, including the SECIS element. The Sec residue in D1 is essential for deiodinase activity since replacement of Sec by Cys results in a 100-fold decrease in catalytic activity, while substitution of Sec by Leu produces an enzymatically inactive protein (42). In addition, D1 is extremely sensitive to inactivation by iodoacetate due to carboxymethylation of a highly reactive residue, probably Sec, in the enzyme active center which is prevented in the presence of substrate (2, 15). Moreover, D1 activity is inhibited by very low concentrations (»10-8 M) of goldthioglucose (GTG), which is known to form very stable complexes with Sec residues, and this inhibition is also competitive with substrate (43). Therefore, Sec is probably the catalytic center of D1.


Two other observations have provided important clues about the possible catalytic mechanism of D1. Firstly, D1 shows ping-pong type reaction kinetics in catalyzing the deiodination of iodothyronines by DTT (2, 15), suggesting that reaction of iodothyronine substrate with D1 produces an enzyme intermediate, from which native enzyme is regenerated by reaction with thiol cofactor (DTT). Secondly, D1 is potently inhibited by PTU, and this inhibition is uncompetitive with substrate and competitive with cofactor, suggesting that PTU and cofactor react with the same enzyme intermediate. Thiouracil derivatives are particularly reactive towards protein sulfenyl iodide (SI) groups, and presumably even more reactive towards selenenyl iodide (SeI) groups, suggesting that such an intermediate is generated in the catalytic cycle of D1. Therefore, the selenolate (Se) group of the native enzyme is thought to act as an acceptor of the iodonium (I+) ion which is substituted in the substrate by a proton, and the SeI intermediate thus generated is reduced back to native enzyme by thiols such as DTT or converted into a dead-end complex by PTU (Fig. 4).



Figure 4. Putative catalytic mechanism of D1 and inhibition by PTU, IAc and GTG.




Unlike the mammalian enzyme, D1 from tilapia was found to be insensitive to PTU inhibition (44). Like all other characterized deiodinases, tilapia D1 also contains a Sec residue in the corresponding position (44). However, two positions downstream from this Sec residue, tilapia D1 features a Pro residue, which is also the case in other fish species and in frog D1. In contrast, all known PTU-sensitive D1 enzymes have a Ser residue at this position. Remarkably, a Pro residue is also present at this position in all known D2 and D3 sequences, which are also PTU-insensitive. Substitution of Pro by Ser in tilapia D1 did not restore PTU sensitivity (44). However, substitution of Pro by Ser in frog D1 (4) as well as in human D2 and D3 not only made these enzymes susceptible to inhibition by PTU but also changed the kinetic mechanism of these enzymes (45). Therefore, in addition to the Sec residue the amino acid two positions downstream plays an important role in the catalytic mechanism of the deiodinases. The lack of PTU inhibition of the tilapia D1Pro>Ser mutant suggests that additional elements of the protein are important for effect of PTU.


D1 activity in liver and kidney is stimulated in hyperthyroidism and decreased in hypothyroidism, representing the regulation of D1 activity by T3 at the transcriptional level  (46). T3 response elements (TREs) have been identified in the upstream region of the D1 gene (47, 48). Studies in TR knockout mice have indicated that D1 expression in liver is primarily controlled by the TRb isoform (49). This agrees well with the colocalization of TRb and D1 in the pericentral zone of rat liver (50). In the thyroid, D1 expression is stimulated by T3, TSH and TSH receptor antibodies, where the effects of the latter are mediated by cAMP  (51, 52).

There is controversy about the contribution of D1 to peripheral T3 production. Different animal models have been studied which may provide a clue about this function of D1. Firstly, rats have been raised on a severely selenium-deficient diet, resulting in a dramatic reduction in liver and kidney D1 activity (53). These rats showed a significant decrease in serum T3 and increase in serum T4, compatible with an important role of D1 in peripheral T4 to T3 conversion. Other studies in rats have demonstrated that D2 and D3 activities in other tissues such as brain are much less affected directly by selenium deficiency (54).It should be noted that in mice lacking the plasma Se carrier selenoprotein P (SePP), thyroid hormone metabolism is preferentially maintained indicating that selenoenzymes have a priority in the organism with respect to selenium supply (55).

Findings in mice do not support an important function of liver and kidney D1 in peripheral T3 production as suggested by selenium deficiency in rats. C3H mice show a strongly reduced hepatic and renal D1 expression compared with other mouse strains (56-58). Yet, their serum T3 levels are comparable, although the C3H mice show some increase in serum T4 suggesting that an increased T4 production may compensate for the decreased T4 to T3 conversion. Serum rT3 levels are mildly elevated as well in C3H mice. In another mouse model, hepatic synthesis of selenoproteins, including D1, is disabled by inactivation of the Sec-specific tRNA  (59). This does not result in any change in circulating thyroid hormone concentrations. Finally, D1 knockout (D1KO) mice have been generated which do not express D1 in any tissue, including thyroid and kidneys (36). These D1KO mice also show normal serum T3 and TSH levels, but like the C3H mice they have elevated serum T4 and rT3 levels as well.

However, we should be careful to draw conclusions about the contribution of D1 to serum T3 homeostasis based on these knock-out mouse models, since even mice without any ORD (D1KO/D2KO mice) are able to maintain normal levels of serum T3 (60), pointing towards a major role played by the thyroid gland as well. Although these data in D1KO/D2KO mice suggest that D1 and D2 may not be essential for the maintenance of the serum T3 level, both enzymes do serve important roles in thyroid hormone homeostasis. Fecal excretion of endogenous iodothyronines was greatly increased in D1KO mice, pointing towards an important role in iodide conservation by serving as a scavenger enzyme in peripheral tissues and the thyroid (36). Similarly, despite normal serum T3 levels in D2KO mice, brain T3 levels as well as the expression of certain T3 responsive genes in the brain was reduced.

Many studies have addressed the question about the contribution of a diminished expression of hepatic D1 to the decrease in serum T3 in rats exposed to fasting or NTI. The results of these studies are confounded by the fact that D1 not only produces T3 from T4 but its expression is also stimulated by T3. In fact, D1 expression is a very sensitive indicator of the thyroid state of the liver (61).

So far, no patients with mutations in D1 have yet been identified. However, several candidate gene association studies have reported on significant associations of single nucleotide polymorphisms (SNPs) in D1 with reciprocal changes in serum T3 versus T4 and rT3 levels (62-64). Recently, a large genome wide association meta-analysis was conducted for serum FT4 levels, and a single nucleotide polymorphism in DIO1 was one of the five genome wide significant hits (65) strongly suggesting an important role for D1 in peripheral thyroid hormone metabolism in humans as well.


Type II iodothyronine deiodinase (D2)



D2 is expressed primarily in the brain, the anterior pituitary gland and (rodent) brown adipose tissue (BAT) (1-5). D2 activity has also been shown in human thyroid (66-68) and skeletal muscle (69), while D2 mRNA is also expressed in human heart (70). Localization of D2 mRNA in rat brain by in situ hybridization has indicated that the enzyme is expressed in astrocytes, in particular in tanycytes lining the third ventricles (71). D2 activity is induced in cultured astrocytes by a variety of factors (73-74). Like the other deiodinases, D2 also forms functional homodimers (38, 39, 75). Regarding cellular localization, D2 is largely present in the endoplasmic reticulum (35).

D2 has only ORD activity, exhibiting low Km and Vmax values, and a slight preference for T4 over rT3 as the substrate. In contrast to D1, it does not catalyze the deiodination of sulfated iodothyronines. The amount of T3 in D2-expressing tissues is derived to a large extent from local conversion of T4 by this enzyme and to a minor extent from plasma T3. In general, D2 activity is increased in hypothyroidism and decreased in hyperthyroidism. Part of this negative control is explained by substrate-induced inactivation of the enzyme by T4 and rT3 (1-5). Reaction of these substrates with D2 induces the ubiquitination of the enzyme, which facilitates its degradation in the proteasomes. However, active D2 may also be recovered by de-ubiquitination of the modified enzyme. Thus, ubiquitination/de-ubiquitination is an important, dynamic mechanism in the regulation of D2 activity in many tissues, except hypothalamic D2 which is less ubiquitinated (72). For a more detailed discussion of this pathway, the reader is referred to excellent studies and reviews published in this area (38, 76-80). Furthermore, Dio2 is a cAMP-responsive gene and as a consequence the adrenergic/cAMP signaling pathway mediates the transcriptional control of D2 (81).In addition, D2 expression is also importantly regulated by ER stress reducing D2 activity by inhibition of  de novo synthesis of the D2 protein (82). Finally, presumably receptor-mediated inhibition of D2 activity by T3 has been demonstrated in pituitary tumor cells (83), and D2 mRNA levels in brain, pituitary and BAT are up-regulated in hypothyroid rats and down-regulated in hyperthyroid animals (84, 85).

The central Sec residue plays an important role in the catalysis and turnover of D2. Replacement of this Sec with Cys results in a 1000-fold increase in the Km value of the substrates T4 and rT3, and a 10-fold decrease in turnover number (86, 87). Substitution of Sec by Ala completely inactivates the enzyme. Also the mechanism of substrate-induced D2 degradation is strongly or completely impaired by replacement of Sec by Cys or Ala, respectively (88), suggesting that modification of this Sec residue during catalysis may be an essential step in the inactivation of the enzyme. Interestingly, mammalian and avian D2 also have a second Sec residue near the C-terminus which, however, is not important for catalytic activity (89).

The D2 gene is located on human chromosome 14q24.2-q24.3. It consists of 2 exons of 0.7 kb and 6.6 kb, seperated by a 7.4 kb intron (2). The SECIS element in the 3’UTR is separated by ~5 kb from the UGA triplet coding for the catalytic Sec residue, resulting in a poor translation efficiency of the D2 mRNA (90). This is even further hampered by the presence of multiple short open reading frames in the 5’UTR of human D2 mRNA (90).



D2 is expressed in human thyroid but not in rat thyroid. Both D2 mRNA and D2 activity in human thyroid are greatly stimulated by TSH and TSH receptor antibodies circulating in patients with Graves’ disease (66, 67). The expression of D2 in human thyroid has been associated with functional TTF-1 binding sites in the 5’ flanking region of the human D2 gene which are lacking in the 5’ flanking region of the rat D2 gene (91). The stimulatory effects of TSH and TSH receptor antibodies on D2 expression in human thyroid are mediated by cAMP, which has been associated with the presence of a cAMP response element (CRE) in the 5’ flanking region of the D2 gene (81, 92). Interestingly, follicular thyroid carcinoma may express high levels of D2, and in case of a large (metastatic) tumor mass this may results in strongly elevated serum T3 levels (93-95).

D2 knockout (D2KO) mice have been generated, showing modest phenotypic changes (96). The homozygous D2KO mice have increased serum T4 and increased TSH levels, but normal levels of T3. The combination of increased serum TSH and T4 is in agreement with an important role of D2 in the negative feedback of T4 at the hypothalamus and pituitary level. However, the normal serum T3 suggests that D2 is not essential for maintaining normal serum T3 levels. However, as mentioned above, even D1KO/D2KO mice are able to maintain normal levels of serum T3 (60), pointing towards a major role for the thyroid gland in serum T3 production as well. In skeletal muscle, D2 levels are higher in slow-twitch than fast-twitch mouse skeletal muscle and are increased in hypothyroidism (97). Specific deletion of D2 in skeletal muscle does not have large effects on thyroid hormone signaling or functional outcomes (98,99).

In contrast to the marked decrease in hepatic and renal (but not thyroidal) D1 activities, the unexpectedly small effects of Se deficiency on tissue D2 and D3 activities in rats, despite that they all appear to be Sec-containing proteins, may be explained by findings that the selenium state of different tissues varies greatly in Se-deficient animals. In addition, the efficiency of the SECIS element to complex with protein factors, such as SBP2, necessary for the read-through of the UGA codon may vary between different seleno­proteins. This could result in the preferred incorporation of Sec into some seleno­proteins, e.g. deiodinases, over others, e.g. glutathione peroxidase  (33).


Despite normal serum T3 levels in D2KO mice, brain T3 levels as well as the expression of certain T3 responsive genes in the brain is reduced, again pointing towards the crucial role of D2 in maintaining local T3 concentrations (96, 105). Several other studies point towards a crucial role for D2 (and D3, see below) in regulating local T3 concentrations, and as a consequence it is know well accepted that these deiodinases can regulate thyroid hormone action at the cellular level during development and tissue stress relatively independent of serum T4 and T3 concentrations (3).

One of the clearest examples of the role of D2 in development is its role in the inner ear. A sharp increase in D2 activity occurs in mouse cochlea at postnatal days 6-8, which is required for normal cochlear development (100). As a consequence, D2KO mice are deaf underlining the importance of D2 in producing local T3 in the cochlea during a critical period of its development (101). Another example of the important role of D2 in development is the observation that D2KO mice have an impaired embryonic BAT development, and as a consequence a permanent thermogenic defect (102, 103). D2KO mice exhibit an impaired thermogenesis in BAT, leading to hypothermia during cold exposure and a greater susceptibility to diet-induced obesity at thermoneutrality (104).

D2 is also essential for maintaining normal local concentrations of T3 in different physiological and pathophysiological situations. D2 has an important role in pituitary and hypothalamic feedback (96). It also plays an essential role for normal myogenesis (106) and in the optimization of bone strength and mineralization (107). Adult D2KO mice have a 50% reduction in bone formation and a generalized increase in skeletal mineralization resulting from a local deficiency of T3 in osteoblasts (101).

D2 is also required for the regeneration of skeletal muscle after injury (106), since regeneration after injury is markedly delayed in D2KO mice. The increase in muscle D2 is mediated via FoxO3, thereby locally increasing intracellular T3 concentrations. Muscle D2 expression during critical illness is differentially regulated, probably related to differences in the inflammatory response and type of pathology (108). In humans, skeletal muscle D2 mRNA expression is modulated by fasting and insulin, but not by hypothyroidism (109). Also in lung tissue, D2 activity increases upon injury. In a mouse model of ventilator-induced lung injury (VILI), lung D2 activity increased (110). D2KO mice had a greater susceptibility to VILI than WT mice, demonstrated by poorer alveoli integrity and quantified by lung chemokine and cytokine induction. Evidence accumulates that D2 is induced during inflammation (e.g. in macrophages) (198, 199).  The neonatal D2 peak in the liver appears relevant for susceptibility to diet-induced steatosis and obesity as shown in hepatocyte-specific D2KO (196).

No patients have been identified with mutations in D2. However, patients with homozygous or compound heterozygous mutations in the SECIS-binding protein SBP2, which is crucial for the synthesis of selenoproteins (111) have abnormal serum thyroid hormone levels: high (F)T4 and rT3, low T3, and somewhat elevated TSH levels. This resembles the changes in thyroid parameters in D2KO mice, although in patients with SBP2 mutations also the expression of functional D1 and D3 is probably affected. As SBP2 deficiency affects many selenoproteins, these patients have a multisystem disorder including growth delay in childhood, hearing loss, enhanced skin sensitivity and infertility (111,112).

Whether polymorphisms in D2 are associated with significant changes in serum thyroid hormone levels or other outcomes such as insulin resistance or osteoarthritis are controversial (62, 113-117, 200). Also uncommon D2 variants are not related to serum thyroid hormone levels (201).  The Thr92Ala polymorphism has been linked with local changes in a specific transcriptional fingerprint, although the relevance needs to be further studied (202).

Type III iodothyronine deiodinase (D3)


D3 activity has been detected in a variety of tissues, i.e. brain, skin, liver, intestine, placenta, and the pregnant rat uterus (1-5, 118-120). D3 expression is usually much higher in fetal than in adult tissues. D3 activity is also highly expressed in certain tumors, including hepatocarcinomas, hemangiomas and basal cell carcinomas (121-124, 203) Because of its expression in fetal tissues and tumors, D3 has been named an oncofetal protein. The enzyme appears to be located in the plasma membrane in the form of a homodimer (38, 125, 126). D3 has only IRD activity, catalyzing the inactivation of T4 and T3 with intermediate Km and Vmax values (Fig. 2).


The expression of D3 in placenta, pregnant uterus, embryonic and fetal tissues may protect developing organs against undue exposure to active thyroid hormone. Also in adult subjects, D3 appears to be an important site for clearance of plasma T3 and production of plasma rT3. In brain and skin, but not in placenta, D3 activity is increased in hyperthyroidism and decreased in hypothyroidism, which in brain is associated with parallel changes in D3 mRNA levels (127).


The D3 gene is located on human chromosome 14q32 and consists of a single exon. In all species, D3 is a selenoprotein homologous with the amino acid sequences of D1 and D3, including the essential Sec residue positioned in a strongly conserved region (Fig. 2). It has been shown that D3 expression is predominantly regulated by TRα1 (128), and studies in TRα1-/- mice have demonstrated a reduced clearance rate of TH due to an impaired regulation of D3 (129).


The presence of Sec in a strongly conserved region of the proteins strongly suggests the same mechanism of deiodination for the different deiodinases. This seems to be contradicted by the widely different susceptibilities of D1 versus D2 and D3 to the different mechanism-based inhibitors PTU, IAc and GTG (Fig. 2). It also seems to be in conflict with previous findings that, in contrast to the ping-pong kinetics of D1, the other two enzymes appear to follow sequential-type kinetics, suggesting the formation of a ternary enzyme-substrate-cofactor complex during catalysis. The differences in enzyme kinetics and PTU inhibition between the deiodinases are determined by the presence of Ser (D1) or Pro (D2,D3) two positions downstream of  Sec, which may somehow influence the reactivity of the catalytic Sec residue (see above). The crystal structure of the catalytic part of D3 suggests a close similarity to 2-Cys peroxiredoxin(s) (Prx) with an  important resolving role for Cys239 by forming a selenenyl-sulfide with Sec170 (204).



D3 plays a very important role in the regulation of local and systemic thyroid hormone bioactivity (1, 123). It has been shown that region-specific expression of D3 in fetal and adult human brain is negatively associated with local tissue T3 levels (130, 131). High expression of D3 in vascular tumors may result in subclinical or even severe hypothyroidism in patients with such tumors, which condition has been termed consumptive hypothyroidism (122, 123, 132). Induction of D3 expression has also been demonstrated in liver and skeletal muscle biopsies from patients who died after severe illness, and D3 activities were correleated to both local and serum rT3 concentrations in these severely sick patients (133-135). Therefore, tissue and circulating iodothyronine levels are regulated not only by changes in the T3-producing deiodinases D1 and D2 but also importantly by reciprocal changes in the T3-degrading deiodinase D3.


D3 knockout (D3KO) mice have been generated, showing remarkable neonatal mortality and growth retardation, althought the severity of the phenotype depends on the genetic background (136-138). In addition, they show largely abnormal thyroid hormone levels, dependent on the age of the animals. Compared with wild-type mice, serum T4 is very low in D3KO mice at all ages, T3 is higher in neonatal mice but much lower in older D3KO mice, while TSH varies between very low in younger to low in older knockout mice. This picture represents a state of central hypothyroidism, suggesting that the setpoint of the hypothalamus-pituitary-thyroid axis is strongly affected by inactivation of D3, which could be due to overexposure of tissues (e.g. the developing hypothalamus) to T3. This is reminiscent of the reports of congenital central hypothyroidism in newborns from mothers who were hyperthyroid during pregnancy (139).


Heterozygous D3KO mice show either almost normal or strongly decreased D3 expression, depending on whether the defective allele is inherited from the mother or the father, respectively, indicating paternal imprinting of the DIO3 gene (136, 205). However, D3 expressed from the maternal D3 allele is important in pancreatic islets to maintain normal glucose homeostasis (206). The DIO3 gene is located in an imprinted region on human chromosome 14 or mouse chromosome 12 which is about 1 Mb in size and comprises the paternally expressed genes DLK1 (delta-like 1) and DIO3, and a large number of in particular maternally expressed non-coding genes. Both Dlk1 and Dio3 expression are elevated in cultured brown pre-adipocytes and down-regulated during differentiation, suggesting that imprinting might control the dosage of these genes to regulate thermogenesis (140). Interestingly, transgenic animals with partial loss of imprinting of this locus show significant lethality in the third postnatal week, associated with developmental delay and failure to maintain UCP1 expression in BAT (141). This defect is the combined result of prolonged elevated expression of Dlk1, leading to a failure in BAT differentiation and subsequent reduced expression of β-adrenergic receptors, and hypothyroidism due to dysregulation of D3.



The important role of hepatic D3 in the regulation of circulating thyroid hormone during development has been investigated in detail in the embryonic chicken (142, 143). These studies have demonstrated that during the last (third) week of incubation there is a gradual increase in plasma T4 levels paralleled by a steady increase in hepatic D1 activity although hepatic D1 mRNA levels do not change much. D3 mRNA and D3 activity show a parallel increase to maximum levels at day 17 of embryonic development, followed by a steep decrease in both parameters in particular immediately before hatching. This is associated with an equally steep increase in plasma T3, strongly suggesting that the latter is importantly and negatively regulated by hepatic D3 activity (142, 143).

A study of the ontogeny of hepatic D1 and D3 during human development has indicated similar profiles of deiodinase expression, with substantial and relatively constant D1 activities from mid-gestation onwards, and high D3 activities at mid-gestation declining to very low levels around term (144). Since in rat liver D1 is not expressed until the last days of gestation, while hepatic D3 expression is low at all stages of rat development (118), these results indicate that the embryonic chicken is a better model than the fetal rat for the regulation of hepatic deiodinases during human development. Injection of the chicken embryo with growth hormone or glucocorticoids induces an acute down-regulation of hepatic D3 mRNA levels and D3 activities, suggesting that the D3 mRNA in the embryonic chicken has a very short half-life, and that transcription of the D3 gene is acutely blocked by these treatments (142). If D3 expression in the fetal human liver is also rapidly down-regulated by GH and glucocorticoids remains to be determined. It is likely that the high D3 activities expressed in the fetal liver, in addition to the high D3 activities in the placenta (145, 146) and perhaps the uterus (119), plays an important role in the regulation of fetal circulating T3 levels and protect the fetus against early T3 exposure.


In recent years, several studies have addressed the role of D3 in regulating local T3 concentrations. It is now well accepted that D3 plays a crucial role in regulating thyroid hormone action at the cellular level during development, relatively independent of serum T4 and T3 concentrations. During development, D3 is expressed in the immature cochlea before D2 (147). Like D2KO mice, D3KO mice display auditory deficits as well. However, in contrast to the retarded cochlear development in D2KO mice, D3KO mice display an accelerated cochlear differentiation due to premature stimulation of TRb. The additional deletion of TRb converts the accelerated cochlear phenotype in D3KO mice to one of delayed differentiation (147), indicating a protective role for D3 in hearing development. This clearly illustrates how different tissues can auto-regulate their developmental response to thyroid hormone through both D2 and D2. D3 also plays a crucial role in cerebellar development, since D3KO mice display abnormally accelerated cerebellar differentiation and locomotor behavioral defects, suggesting that D3 protects cerebellar tissues from inappropriate, premature stimulation by thyroid hormone (148, 207). This cerebellar phenotype results specifically from inappropriate stimulation of the TRa1 receptor isoform, since the additional deletion of TRa1 reversed the cerebellar phenotype. Also, additional deletion of MCT8 in the D3KO mice ameliorates the phenotype indicating the relevance of MCT8 for intracellular T3 levels (208). Similarly, D3 protects cones to unlimited T3 exposure in the immature mouse retina. As a consequence, approximately 80% of cones are lost through neonatal cell death in D3KO mice (149). Similar results were obtained in zebrafish (209). D3 appears also a critical factor in testis development via influencing local thyroid hormone bioavailability (210).  Furthermore, protection against untimed T3 exposure by D3 in pancreatic β-cells during development is essential for normal islet function and glucose homeostasis (150). As a consequence, D3KO mice have impaired insulin secretion in response to glucose stimulation. In contrast to most tissues, D3 expression remains throughout adulthood in human and mouse β-cells. However, whether dysregulation of Dio3 might play a role in different states of impaired insulin secretion remains to be explored in future studies (150). In addition, less fat tissue is seen in D3KO mice, which is mediated through in the leptin-melanocortin system (211).

In addition to its crucial role during development, D3 activity is also important in regulating thyroid hormone action at the cellular level in different pathophysiological conditions. Induction of D3 expression has been documented in the hypertrophic or failing heart resulting from pressure overload or myocardial infarction (151-153). Hypoxia-inducible factor 1a (HIF-1a) induces local thyroid hormone inactivation by inducing D3 during hypoxia (152), suggesting a mechanism of down-regulating metabolism during ischemia. In neuronal hypoxia, translocation of D3 to the nucleus is mediated by Hsp-40, thereby facilitating local inactivation of thyroid hormone and reducing ischemia-induced hypoxic brain damage (154). Heterozygous D3KO mice constitute a model of cardiac D3 inactivation in an otherwise systemically euthyroid animal (155). These mice have normal hearts but later develop restrictive cardiomyopathy due to cardiac-specific increase in thyroid hormone signaling. In addition, heterozygous D3KO mice are more vulnerable to isoproterenol, further worsening the restrictive cardiomyopathy and leading to congestive heart failure and increased mortality (155). D3 activity is also induced in liver and muscle of critically ill patients (133-135). See (156) for an excellent overview of the changes in local thyroid hormone metabolism during illness and inflammation. Interestingly, in a mouse model of turpentine-induced tissue inflammation, high D3 expression in invading granulocytes has also been reported (157, 158). Recent studies also documented D3 in human neutrophils (212). Furthermore, D1 decreases and D3 increases are seen in livers of premature and normal aging mice, hinting that changes in deiodinases are mediated via DNA damage and might contribute to the beneficial survival response (213).

Several recent studies have demonstrated that local regulation of thyroid hormone action also plays a crucial role in repair mechanisms, for example D3 in liver (159) and brain (160), and D2 and D3 in muscle (106, 214). The reciprocal changes in D2 and D3 are shown in elegant studies demonstrating that D2 is induced to allow proper differentiation after muscle injury, while D3 induction in proliferating muscle cells protects against excessive local thyroid hormone concentrations, preventing apoptosis (106, 214). Furthermore, D2 and D3 activities are regulated by a variety of growth factors and morphogens, which are important mediators of tissue injury repair (161).  After a large hepatectomy, ‘stem-like’ cells switch from a quiescent state to a proliferative state. During these processes, many fetal genes are reactivated (162). Among them, D3 activity was increased 10-fold and D3 mRNA expression was increased 3-fold 20 h after partial hepatectomy in rats. No significant effects on D1 and D2 activities or mRNA expression were found after partial hepatectomy in mice (159). This leads to the concept that a coordinated regulation of thyroid hormone action is essential in the control of the tight balance between proliferation and differentiation in the regeneration processes. Induction of D3 expression in the early phases of regeneration may therefore very well correlate with a requirement of increased cellular proliferation in these circumstances (3, 161).


The balance between proliferation and differentiation is disturbed in cancer, and D3 is turned on in several malignant cell lines and human cancers (3, 163). D3 activity in these cancers can be very high and may even lead to so-called consumptive hypothyroidism (123, 132, 203) . In basal cell carcinomas, as well as in primary proliferating keratinocytes, Sonic hedgehog  (Shh) increases the expression of D3, acting via a conserved Gli2 binding site on the human Dio3 promoter (121, 215). This suggests that Shh may induce local down-regulation of thyroid hormone activity. Interestingly, knockdown of D3 caused a 5-fold reduction in the growth of basal cell carcinoma xenografts in nude mice (121), suggesting that D3 up-regulation provides an advantage for proliferating tumor cells. This appears to be mediated by miR21 that reduces the tumor suppressor gene GRHL3 which in turn increases D3 expression (216). Interestingly, a recent study in papillary thyroid carcinoma demonstrated an  association between increased levels of D3 activity and advanced disease (164). However, since only a few tumors over-express D3, D3 expression seems not be a necessary step in tumorigenesis.


Iodothyronine sulfotransferases

Sulfotransferases represent a family of enzymes with a monomer molecular weight of »34 kDa, located in the cytoplasmic fraction of different tissues, in particular liver, kidney, intestine and brain (165). They catalyze the transfer of sulfate from 3′-phosphoadenosine-5′-phosphosulfate (PAPS) to usually a hydroxyl group of the substrate (165). On the basis of substrate specificity and amino acid sequence homology, mainly two sulfotransferase families have been recognized in human tissues, i.e. the phenol sulfo-transferases (SULT1 family), including estrogen sulfotransferase, and the hydroxysteroid sulfotransferases (SULT2 family) (165). Different phenol sulfotransferases have been identified with significant activity towards iodothyronines. These include human SULT1A1, 1A2, 1A3, 1B1 and 1C2 (Table 1) (166-174). These studies have indicated a large substrate preference of the recombinant enzymes as well as the native enzymes in human liver and kidney for 3,3’T2, the sulfation of which is catalyzed orders of magnitude faster than that of T3 or rT3, while sulfation of T4 is hardly detectable (168).


Surprisingly, it has also been demonstrated that human estrogen sulfo-transferase (SULT1E1) is an important isoenzyme for sulfation of thyroid hormone. Although human SULT1E1 shows much higher affinities for estrogens (Km »nM) than for iodothyronines (Km »μM), it is about as efficient as other isoenzymes in sulfating 3,3’T2 and T3, and much more efficient in sulfating rT3 and T4 (169). Human tissues known to express SULT1E1 include liver, uterus, and mammary gland (175). In particular the enzyme expressed in the endometrium may be a significant source for the high levels of iodothyronine sulfates in human fetal plasma (see below). Recently, different human SULTs have also been shown to catalyze the sulfation of iodothyronamines (Table 1) (172).


Deiodination of iodothyronine sulfates

Although D1 is capable of converting T4 with similar efficiency by ORD to T3 and by IRD to rT3, this is changed dramatically after sulfate conjugation, i.e. IRD of T4S by rat D1 is accelerated »200-fold, whereas ORD of T4S becomes undetectable (Fig. 5) (17). IRD of T3 by rat and human D1 is also markedly stimulated (»40-fold) by sulfation (Fig. 5)(17). As mentioned before, rT3 is by far the preferred D1 substrate; its ORD is not influenced by sulfation, suggesting that the catalytic efficiency of D1 is already optimal with nonsulfated rT3 (17). While sulfation inhibits ORD of T4 and is without effect on ORD of rT3, it markedly stimulates ORD of 3,3’-T2 (Fig. 5). Thus, sulfation facilitates the IRD of T4 and T3, while it either inhibits (T4), does not affect (rT3) or markedly stimulates (3,3’T2) the ORD of other substrates (17).



Figure 5. Efficiency of deiodination of iodothyronines and their sulfates by rat liver D1.

   *) Vmax (pmol/min/mg protein)/Km (µM) ratio.



The mechanism by which sulfation stimulates especially the IRD of different substrates remains unclear. In some cases sulfation primarily effects an increase in Vmax, while in others there is a predominant decrease in apparent Km value. The facilitated deiodination of sulfated iodothyronines by rat liver D1 may be due to interaction of the negatively charged sulfate group with protonated residues in the active center of this basic protein. The effect of sulfation on deiodination of iodothyronines is both conjugation type and deiodinase type-specific since D1 does not catalyze the deiodination of T3 glucuronide, while D2 and D3 do not accept T4S and/or T3S as substrates.


Importance of thyroid hormone sulfation

Serum concentrations of T4S, T3S, rT3S and 3,3’T2S are low in normal human subjects but they are high in fetal and cord blood, in patients with NTI, and in patients treated with the D1 inhibitor (16, 176). The serum T3S/T3 ratio is also increased in hypothyroid patients (177, 178). High iodothyronine sulfate levels have also been detected in human fetal and neonatal serum and amniotic fluid (16). The high serum iodothyronine sulfate levels during NTI, hypothyroidism and fetal development have been ascribed to a low peripheral D1 activity in these conditions (17, 18). These results are in accordance with studies in rats, showing marked increases in the serum concentration and biliary excretion of iodothyronine sulfates when hepatic and renal D1 activities are decreased by D1 inhibitors or selenium deficiency (17). These changes are not caused by an increased sulfation of iodothyronines but by a decreased clearance of the sulfated iodothyronines by D1.

Thus, sulfation is a primary step leading to the irreversible degradation of T4 and T3 by D1. However, if D1 activity is low, inactivation of thyroid hormone by sulfation is reversible due to expression of sulfatases in different tissues and by intestinal bacteria (179). It has been speculated that especially in the fetus T3S has an important function as a reservoir from which active T3 may be released in a tissue-specific and time-dependent manner(17, 180).

Wu and coworkers have demonstrated the presence of a 3,3’T2S cross-reacting substance, termed compound W, in the serum and urine of pregnant women  (16, 181). Interestingly, compound W is derived from the fetus and its concentration in maternal serum may reflect fetal thyroid state (16, 181). The structure of compound W remains to be identified.


Like sulfation, glucuronidation is a phase II metabolic reaction that increases the water-solubility of endogenous and exogenous compounds to increase their biliary or urinary excretion. Glucuronidation is catalyzed by UDP-glucuronyltransferases (UGTs) that utilize UDP-glucuronic acid (UDPGA) as cofactor. UGTs are localized in the endoplasmic reticulum of predominantly liver, kidney and intestine. Most UGTs are members of the UGT1A and UGT2B families (182).

Iodothyronines are also metabolized by glucuronidation, although this appears more important in rodents than in humans (183). Especially in rodents, metabolism of thyroid hormone is accelerated through induction of T4-glucuronidating UGTs by different classes of compounds, including barbiturates, fibrates and PCBs (184-186). This may result in a hypothyroid state as the thyroid gland is not capable of compensating for the increased hormone loss. In humans, thyroid function may be affected by induction of T4 glucuronidation by anti-epileptics, but development of overt hypothyroidism is rare (187).

Glucuronidation of T4 and T3 is catalyzed by different members of the UGT1A family (Table 2) (188-191). Usually, this involves the glucuronidation of the hydroxyl group, but human UGT1A3 also catalyzes the glucuronidation of the side-chain carboxyl group, with formation of so-called acyl glucuronides (189). Interestingly, Tetrac and Triac are much more rapidly glucuronidated in human liver than T4 and T3, and this occurs predominantly by acyl glucuronidation (192). Acyl glucuronides are reactive compounds that may form covalent complexes with proteins. It is unknown if this is a significant route for the formation of covalent iodothyronine-protein complexes.

Integrated physiological role of thyroid hormone metabolism

Since most actions of thyroid hormone are initiated by binding of T3 to its nuclear receptors, it is important to consider the role of the processes discussed above in the regulation of nuclear T3. There are two sources of intracellular T3, i.e. T3 derived from plasma T3, and T3 produced locally from T4, and the degree to which they contribute to the occupied receptors varies among the different tissues in different physiological and pathophysiological states (1, 3, 5, 76, 98). The liver and kidneys are typical of most tissues in the body in which most of the T3 specifically bound to the T3 receptor is derived directly from plasma. In cerebral cortex, BAT, and anterior pituitary there is a substantial contribution to nuclear T3 from locally produced T3. Local T3 production may be an autocrine process, where T3 is produced in the same cells where it acts, or a paracrine mechanism, where T3 production and action take place in neighboring cells. The latter appears very important for T3 action in the brain, where neurons are the primary target cells for T3 produced by D2 expressed in nearby astrocytes (193-195).


D3 plays an additional important role in maintaining intracellular T3 concentrations in these tissues by catalyzing the degradation of T3 in case of excess or by diverting the metabolism of T4 to rT3. Indeed, the adaptations of deiodinase activities in response to changes in thyroid state are thought to serve the purpose of keeping intracellular T3 in the brain constant. Thus, when T4 supply is decreased in hypothyroidism, both D1 and D3 activities are down-regulated, so that relatively more T4 is available for conversion to T3 by D2 in the brain, the activity of which is up-regulated. Opposite changes occur in hyperthyroidism. These adaptations are not only important for the optimal function of the brain in adult life, they are also essential for the development of the brain which is critically dependent on thyroid hormone. Although the adaptations in deiodinase activities during hypo- or hyper­thyroidism go a long way in securing T3 availability in the brain, in severe iodine deficiency they may not fully compensate for the extreme decrease in T4 supply. This may result in severe impairment of neurological development in the child even when plasma T3 levels in the mother are sufficient to maintain a euthyroid state.


The critical role of deiodination in regulating local thyroid hormone action is clearly illustrated by the developing cochlea, where D3 is expressed before the onset of D2 activity (101, 147), preventing too much or too little hormonal stimulation at inappropriate stages in development. At immature stages, D3 limits stimulation by T3. Postnatally, a double switch occurs with a decline in D3 and an increase D2, resulting in a local T3 surge which is independent of serum T3 levels and triggers the onset of auditory function. A similar double switch, preventing premature T3 stimulation, occurs in the developing cerebellum (148), and D3 expression has also been shown to be crucial for normal retinal (149) and pancreatic b-cell development (150). Similarly, local thyroid hormone activation by D2 has been shown to be essential for normal BAT development (102) and myogenesis (106) as well.

Deiodinases are not only essential in controlling local thyroid hormone action during development, but also for normal function of adult tissues such as hypothalamus, pituitary, bone, and brown adipose tissue (96, 102, 107). Finally, deiodination is also important in regulating thyroid hormone bioactivity in different pathophysiological conditions, such as hypoxia, myocardial infarction, neuronal ischemia, critical illness, tissue injury, regeneration, and cancer (106, 121, 134, 152-154, 156, 157, 159). D2KO mice are more vulnerable to ventilator induced lung injury (110), whereas heterozygous D3KO mice are more vulnerable to a chemically induced worsening of restrictive cardiomyopathy, leading to congestive heart failure and increased mortality (155). The high expression of D3 in regenerating liver tissue and certain tumors and the crucial role of D2 and D3 in muscle regeneration (3, 106, 123, 159, 197, 214) suggest that coordinated regulation of thyroid hormone action is essential in the control of the tight balance between proliferation and differentiation in the regeneration processes, and that high expression of D3 may also be an advantage in proliferating tumor cells (98, 101, 147). The joint coordination between the different deiodinases is seen in mice lacking all deiodinases (D1/D2/D3 KO) versus individual deiodinase KO mice. D1/D2/D3 KO mice are viable and some features resulting from deficiency of either of the deiodinases is mitigated by the simultaneous lack of all deiodinases (217).



  1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006 Oct;116(10):2571-9.
  2. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002 Feb;23(1):38-89.
  3. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev. 2008 Dec;29(7):898-938.
  4. Gereben B, McAninch EA, Ribeiro MO, Bianco AC. Scope and limitations of iodothyronine deiodinases in hypothyroidism. Nat Rev Endocrinol. 2015 Nov;11(11):642-52.
  5. Larsen PR, Zavacki AM. Role of the Iodothyronine Deiodinases in the Physiology and Pathophysiology of Thyroid Hormone Action. Eur Thyroid J. 2012.
  6. Escobar-Morreale HF, del Rey FE, Obregon MJ, de Escobar GM. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology. 1996 Jun;137(6):2490-502.
  7. Escobar-Morreale HF, Obregon MJ, Escobar del Rey F, Morreale de Escobar G. Tissue-specific patterns of changes in 3,5,3′-triiodo-L-thyronine concentrations in thyroidectomized rats infused with increasing doses of the hormone. Which are the regulatory mechanisms? Biochimie. 1999 May;81(5):453-62.
  8. Bunevicius R, Jakubonien N, Jurkevicius R, Cernicat J, Lasas L, Prange AJ, Jr. Thyroxine vs thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves’ disease. Endocrine. 2002 Jul;18(2):129-33.
  9. Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2006 Jul;91(7):2592-9.
  10. Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, Galan JM, Barrios V, Sancho J. Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med. 2005 Mar 15;142(6):412-24.
  11. Hennemann G, Docter R, Visser TJ, Postema PT, Krenning EP. Thyroxine plus low-dose, slow-release triiodothyronine replacement in hypothyroidism: proof of principle. Thyroid. 2004 Apr;14(4):271-5.
  12. Appelhof BC, Peeters RP, Wiersinga WM, Visser TJ, Wekking EM, Huyser J, et al. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3′-triiodothyronine therapy. J Clin Endocrinol Metab. 2005 Nov;90(11):6296-9.
  13. Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009 May;94(5):1623-9.
  14. van der Deure WM, Appelhof BC, Peeters RP, Wiersinga WM, Wekking EM, Huyser J, et al. Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. Clin Endocrinol (Oxf). 2008 Nov;69(5):804-11.
  15. Visser TJ. Pathways of thyroid hormone metabolism. Acta Med Austriaca. 1996;23(1-2):10-6.
  16. Wu SY, Green WL, Huang WS, Hays MT, Chopra IJ. Alternate pathways of thyroid hormone metabolism. Thyroid. 2005 Aug;15(8):943-58.
  17. Visser TJ. Role of sulfation in thyroid hormone metabolism. Chem Biol Interact. 1994 Jun;92(1-3):293-303.
  18. Peeters RP, Kester MH, Wouters PJ, Kaptein E, van Toor H, Visser TJ, et al. Increased thyroxine sulfate levels in critically ill patients as a result of a decreased hepatic type I deiodinase activity. J Clin Endocrinol Metab. 2005 Dec;90(12):6460-5.
  19. Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, et al. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med. 2004 Jun;10(6):638-42.
  20. Piehl S, Hoefig CS, Scanlan TS, Kohrle J. Thyronamines–past, present, and future. Endocr Rev. 2011 Feb;32(1):64-80.
  21. DeBarber AE, Geraci T, Colasurdo VP, Hackenmueller SA, Scanlan TS. Validation of a liquid chromatography-tandem mass spectrometry method to enable quantification of 3-iodothyronamine from serum. J Chromatogr A. 2008 Nov 7;1210(1):55-9.
  22. Manni ME, De Siena G, Saba A, Marchini M, Landucci E, Gerace E, et al. Pharmacological effects of 3-iodothyronamine (T1AM) in mice include facilitation of memory acquisition and retention and reduction of pain threshold. Br J Pharmacol. 2012 Aug 13.
  23. Panas HN, Lynch LJ, Vallender EJ, Xie Z, Chen GL, Lynn SK, et al. Normal thermoregulatory responses to 3-iodothyronamine, trace amines and amphetamine-like psychostimulants in trace amine associated receptor 1 knockout mice. J Neurosci Res. 2010 Jul;88(9):1962-9.
  24. Hoefig CS, Kohrle J, Brabant G, Dixit K, Yap B, Strasburger CJ, et al. Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. J Clin Endocrinol Metab. 2011 Jun;96(6):1864-72.
  25. Piehl S, Heberer T, Balizs G, Scanlan TS, Smits R, Koksch B, et al. Thyronamines are isozyme-specific substrates of deiodinases. Endocrinology. 2008 Jun;149(6):3037-45.
  26. Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F. Metabolic effects of thyroid hormone derivatives. Thyroid. 2008 Feb;18(2):239-53.
  27. Radetti G, Persani L, Molinaro G, Mannavola D, Cortelazzi D, Chatterjee VK, et al. Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid. 1997 Oct;7(5):775-8.
  28. Paris M, Escriva H, Schubert M, Brunet F, Brtko J, Ciesielski F, et al. Amphioxus postembryonic development reveals the homology of chordate metamorphosis. Curr Biol. 2008 Jun 3;18(11):825-30.
  29. Klootwijk W, Friesema EC, Visser TJ. A nonselenoprotein from amphioxus deiodinates triac but not T3: is triac the primordial bioactive thyroid hormone? Endocrinology. 2011 Aug;152(8):3259-67.
  30. de Lange P, Cioffi F, Senese R, Moreno M, Lombardi A, Silvestri E, et al. Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats. Diabetes. 2011 Nov;60(11):2730-9.
  31. Lanni A, Moreno M, Lombardi A, de Lange P, Silvestri E, Ragni M, et al. 3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. FASEB J. 2005 Sep;19(11):1552-4.
  32. Berry MJ, Banu L, Larsen PR. Type I iodothyronine deiodinase is a selenocysteine-containing enzyme. Nature. 1991 Jan 31;349(6308):438-40.
  33. Berry MJ. Insights into the hierarchy of selenium incorporation. Nat Genet. 2005 Nov;37(11):1162-3.
  34. Hoffmann PR, Berry MJ. Selenoprotein synthesis: a unique translational mechanism used by a diverse family of proteins. Thyroid. 2005 Aug;15(8):769-75.
  35. Baqui MM, Gereben B, Harney JW, Larsen PR, Bianco AC. Distinct subcellular localization of transiently expressed types 1 and 2 iodothyronine deiodinases as determined by immunofluorescence confocal microscopy. Endocrinology. 2000 Nov;141(11):4309-12.
  36. Schneider MJ, Fiering SN, Thai B, Wu SY, St Germain E, Parlow AF, et al. Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice. Endocrinology. 2006 Jan;147(1):580-9.
  37. Toyoda N, Berry MJ, Harney JW, Larsen PR. Topological analysis of the integral membrane protein, type 1 iodothyronine deiodinase (D1). J Biol Chem. 1995 May 19;270(20):12310-8.
  38. Curcio-Morelli C, Gereben B, Zavacki AM, Kim BW, Huang S, Harney JW, et al. In vivo dimerization of types 1, 2, and 3 iodothyronine selenodeiodinases. Endocrinology. 2003 Mar;144(3):937-46.
  39. Leonard JL, Simpson G, Leonard DM. Characterization of the protein dimerization domain responsible for assembly of functional selenodeiodinases. J Biol Chem. 2005 Mar 25;280(12):11093-100.
  40. Leonard JL, Visser TJ, Leonard DM. Characterization of the subunit structure of the catalytically active type I iodothyronine deiodinase. J Biol Chem. 2001 Jan 26;276(4):2600-7.
  41. Hoefig CS, Renko K, Piehl S, Scanlan TS, Bertoldi M, Opladen T et al. Does the aromatic L-amino acid decarboxylase contribute to thyronamine biosynthesis? Mol Cell Endocrinol. 2012 Feb 26;349(2):195-201.
  42. Berry MJ, Maia AL, Kieffer JD, Harney JW, Larsen PR. Substitution of cysteine for selenocysteine in type I iodothyronine deiodinase reduces the catalytic efficiency of the protein but enhances its translation. Endocrinology. 1992 Oct;131(4):1848-52.
  43. Berry MJ, Kieffer JD, Harney JW, Larsen PR. Selenocysteine confers the biochemical properties characteristic of the type I iodothyronine deiodinase. J Biol Chem. 1991 Aug 5;266(22):14155-8.
  44. Sanders JP, Van der Geyten S, Kaptein E, Darras VM, Kuhn ER, Leonard JL, et al. Characterization of a propylthiouracil-insensitive type I iodothyronine deiodinase. Endocrinology. 1997 Dec;138(12):5153-60.
  45. Callebaut I, Curcio-Morelli C, Mornon JP, Gereben B, Buettner C, Huang S, et al. The iodothyronine selenodeiodinases are thioredoxin-fold family proteins containing a glycoside hydrolase clan GH-A-like structure. J Biol Chem. 2003 Sep 19;278(38):36887-96.
  46. O’Mara BA, Dittrich W, Lauterio TJ, St Germain DL. Pretranslational regulation of type I 5′-deiodinase by thyroid hormones and in fasted and diabetic rats. Endocrinology. 1993 Oct;133(4):1715-23.
  47. Jakobs TC, Schmutzler C, Meissner J, Kohrle J. The promoter of the human type I 5′-deiodinase gene–mapping of the transcription start site and identification of a DR+4 thyroid-hormone-responsive element. Eur J Biochem. 1997 Jul 1;247(1):288-97.
  48. Toyoda N, Zavacki AM, Maia AL, Harney JW, Larsen PR. A novel retinoid X receptor-independent thyroid hormone response element is present in the human type 1 deiodinase gene. Mol Cell Biol. 1995 Sep;15(9):5100-12.
  49. Amma LL, Campos-Barros A, Wang Z, Vennstrom B, Forrest D. Distinct tissue-specific roles for thyroid hormone receptors beta and alpha1 in regulation of type 1 deiodinase expression. Mol Endocrinol. 2001 Mar;15(3):467-75.
  50. Zandieh Doulabi B, Platvoet-ter Schiphorst M, van Beeren HC, Labruyere WT, Lamers WH, Fliers E, et al. TR(beta)1 protein is preferentially expressed in the pericentral zone of rat liver and exhibits marked diurnal variation. Endocrinology. 2002 Mar;143(3):979-84.
  51. Toyoda N, Nishikawa M, Horimoto M, Yoshikawa N, Mori Y, Yoshimura M, et al. Synergistic effect of thyroid hormone and thyrotropin on iodothyronine 5′-deiodinase in FRTL-5 rat thyroid cells. Endocrinology. 1990 Sep;127(3):1199-205.
  52. Toyoda N, Nishikawa M, Horimoto M, Yoshikawa N, Mori Y, Yoshimura M, et al. Graves’ immunoglobulin G stimulates iodothyronine 5′-deiodinating activity in FRTL-5 rat thyroid cells. J Clin Endocrinol Metab. 1990 Jun;70(6):1506-11.
  53. Beckett GJ, MacDougall DA, Nicol F, Arthur R. Inhibition of type I and type II iodothyronine deiodinase activity in rat liver, kidney and brain produced by selenium deficiency. Biochem J. 1989 May 1;259(3):887-92.
  54. Chanoine JP, Safran M, Farwell AP, Dubord S, Alex S, Stone S, et al. Effects of selenium deficiency on thyroid hormone economy in rats. Endocrinology. 1992 Oct;131(4):1787-92.
  55. Schomburg L, Riese C, Michaelis M, Griebert E, Klein MO, Sapin R, et al. Synthesis and metabolism of thyroid hormones is preferentially maintained in selenium-deficient transgenic mice. Endocrinology. 2006 Mar;147(3):1306-13.
  56. Berry MJ, Grieco D, Taylor BA, Maia AL, Kieffer JD, Beamer W, et al. Physiological and genetic analyses of inbred mouse strains with a type I iodothyronine 5′ deiodinase deficiency. J Clin Invest. 1993 Sep;92(3):1517-28.
  57. Maia AL, Berry MJ, Sabbag R, Harney JW, Larsen PR. Structural and functional differences in the dio1 gene in mice with inherited type 1 deiodinase deficiency. Mol Endocrinol. 1995 Aug;9(8):969-80.
  58. Schoenmakers CH, Pigmans IG, Poland A, Visser TJ. Impairment of the selenoenzyme type I iodothyronine deiodinase in C3H/He mice. Endocrinology. 1993 Jan;132(1):357-61.
  59. Streckfuss F, Hamann I, Schomburg L, Michaelis M, Sapin R, Klein MO, et al. Hepatic deiodinase activity is dispensable for the maintenance of normal circulating thyroid hormone levels in mice. Biochem Biophys Res Commun. 2005 Nov 18;337(2):739-45.
  60. Galton VA, Schneider MJ, Clark AS, St Germain DL. Life without thyroxine to 3,5,3′-triiodothyronine conversion: studies in mice devoid of the 5′-deiodinases. Endocrinology. 2009 Jun;150(6):2957-63.
  61. Zavacki AM, Ying H, Christoffolete MA, Aerts G, So E, Harney JW, et al. Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse. Endocrinology. 2005 Mar;146(3):1568-75.
  62. de Jong FJ, Peeters RP, den Heijer T, van der Deure WM, Hofman A, Uitterlinden AG, et al. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. J Clin Endocrinol Metab. 2007 Feb;92(2):636-40.
  63. Panicker V, Cluett C, Shields B, Murray A, Parnell KS, Perry JR, et al. A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. J Clin Endocrinol Metab. 2008 Aug;93(8):3075-81.

64        Medici M, van der Deure WM, Verbiest M, Vermeulen SH, Hansen PS, Kiemeney LA, et al. A large-scale association analysis of 68 thyroid hormone pathway genes with serum TSH and FT4 levels. Eur J Endocrinol. 2011 May;164(5):781-8.

  1. Porcu E, Medici M, Pistis G, Volpato CB, Wilson SG, Cappola AR et al. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genet. 2013;9(2):e1003266.
  2. Imai Y, Toyoda N, Maeda A, Kadobayashi T, Fangzheng G, Nishikawa M, et al. Type 2 iodothyronine deiodinase expression is upregulated by the protein kinase A-dependent pathway and is downregulated by the protein kinase C-dependent pathway in cultured human thyroid cells. Thyroid. 2001 Oct;11(10):899-907.
  3. Murakami M, Araki O, Hosoi Y, Kamiya Y, Morimura T, Ogiwara T, et al. Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology. 2001 Jul;142(7):2961-7.
  4. Salvatore D, Tu H, Harney JW, Larsen PR. Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J Clin Invest. 1996 Aug 15;98(4):962-8.
  5. Hosoi Y, Murakami M, Mizuma H, Ogiwara T, Imamura M, Mori M. Expression and regulation of type II iodothyronine deiodinase in cultured human skeletal muscle cells. J Clin Endocrinol Metab. 1999 Sep;84(9):3293-300.
  6. Dentice M, Morisco C, Vitale M, Rossi G, Fenzi G, Salvatore D. The different cardiac expression of the type 2 iodothyronine deiodinase gene between human and rat is related to the differential response of the Dio2 genes to Nkx-2.5 and GATA-4 transcription factors. Mol Endocrinol. 2003 Aug;17(8):1508-21.
  7. Guadano-Ferraz A, Obregon MJ, St Germain DL, Bernal J. The type 2 iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat brain. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10391-6.
  8. Werneck de Castro JP, Fonseca TL, Ueta CB, McAninch EA, Abdalla S, Wittmann G et al. Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. J Clin Invest. 2015 Feb;125(2):769-81.
  9. Courtin F, Liva P, Gavaret JM, Toru-Delbauffe D, Pierre M. Induction of 5-deiodinase activity in astroglial cells by 12-O-tetradecanoylphorbol 13-acetate and fibroblast growth factors. J Neurochem. 1991 Apr;56(4):1107-13.
  10. Lamirand A, Mercier G, Ramauge M, Pierre M, Courtin F. Hypoxia stabilizes type 2 deiodinase activity in rat astrocytes. Endocrinology. 2007 Oct;148(10):4745-53.
  11. Simpson GI, Leonard DM, Leonard JL. Identification of the key residues responsible for the assembly of selenodeiodinases. J Biol Chem. 2006 May 26;281(21):14615-21.
  12. Bianco AC, Larsen PR. Cellular and structural biology of the deiodinases. Thyroid. 2005 Aug;15(8):777-86.
  13. Dentice M, Bandyopadhyay A, Gereben B, Callebaut I, Christoffolete MA, Kim BW, et al. The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nat Cell Biol. 2005 Jul;7(7):698-705.
  14. Kim BW, Zavacki AM, Curcio-Morelli C, Dentice M, Harney JW, Larsen PR, et al. Endoplasmic reticulum-associated degradation of the human type 2 iodothyronine deiodinase (D2) is mediated via an association between mammalian UBC7 and the carboxyl region of D2. Mol Endocrinol. 2003 Dec;17(12):2603-12.
  15. Sagar GD, Gereben B, Callebaut I, Mornon JP, Zeold A, da Silva WS, et al. Ubiquitination-induced conformational change within the deiodinase dimer is a switch regulating enzyme activity. Mol Cell Biol. 2007 Jul;27(13):4774-83.
  16. Arrojo EDR, Fonseca TL, Werneck-de-Castro JP, Bianco AC. Role of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling. Biochim Biophys Acta. 2012 Aug 29.
  17. Canettieri G, Celi FS, Baccheschi G, Salvatori L, Andreoli M, Centanni M. Isolation of human type 2 deiodinase gene promoter and characterization of a functional cyclic adenosine monophosphate response element. Endocrinology. 2000 May;141(5):1804-13.
  18. Arrojo EDR, Fonseca TL, Castillo M, Salathe M, Simovic G, Mohacsik P, et al. Endoplasmic reticulum stress decreases intracellular thyroid hormone activation via an eIF2a-mediated decrease in type 2 deiodinase synthesis. Mol Endocrinol. 2011 Dec;25(12):2065-75.
  19. Halperin Y, Shapiro LE, Surks MI. Down-regulation of type II L-thyroxine, 5′-monodeiodinase in cultured GC cells: different pathways of regulation by L-triiodothyronine and 3,3′,5′-triiodo-L-thyronine. Endocrinology. 1994 Oct;135(4):1464-9.
  20. Burmeister LA, Pachucki J, St Germain DL. Thyroid hormones inhibit type 2 iodothyronine deiodinase in the rat cerebral cortex by both pre- and posttranslational mechanisms. Endocrinology. 1997 Dec;138(12):5231-7.
  21. Kim SW, Harney JW, Larsen PR. Studies of the hormonal regulation of type 2 5′-iodothyronine deiodinase messenger ribonucleic acid in pituitary tumor cells using semiquantitative reverse transcription-polymerase chain reaction. Endocrinology. 1998 Dec;139(12):4895-905.
  22. Buettner C, Harney JW, Larsen PR. The role of selenocysteine 133 in catalysis by the human type 2 iodothyronine deiodinase. Endocrinology. 2000 Dec;141(12):4606-12.
  23. Kuiper GG, Klootwijk W, Visser TJ. Substitution of cysteine for a conserved alanine residue in the catalytic center of type II iodothyronine deiodinase alters interaction with reducing cofactor. Endocrinology. 2002 Apr;143(4):1190-8.
  24. Steinsapir J, Bianco AC, Buettner C, Harney J, Larsen PR. Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme’s active center. Endocrinology. 2000 Mar;141(3):1127-35.
  25. Salvatore D, Harney JW, Larsen PR. Mutation of the Secys residue 266 in human type 2 selenodeiodinase alters 75Se incorporation without affecting its biochemical properties. Biochimie. 1999 May;81(5):535-8.
  26. Gereben B, Kollar A, Harney JW, Larsen PR. The mRNA structure has potent regulatory effects on type 2 iodothyronine deiodinase expression. Mol Endocrinol. 2002 Jul;16(7):1667-79.
  27. Gereben B, Salvatore D, Harney JW, Tu HM, Larsen PR. The human, but not rat, dio2 gene is stimulated by thyroid transcription factor-1 (TTF-1). Mol Endocrinol. 2001 Jan;15(1):112-24.
  28. Bartha T, Kim SW, Salvatore D, Gereben B, Tu HM, Harney JW, et al. Characterization of the 5′-flanking and 5′-untranslated regions of the cyclic adenosine 3′,5′-monophosphate-responsive human type 2 iodothyronine deiodinase gene. Endocrinology. 2000 Jan;141(1):229-37.
  29. Kim BW, Daniels GH, Harrison BJ, Price A, Harney JW, Larsen PR, et al. Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. J Clin Endocrinol Metab. 2003 Feb;88(2):594-8.
  30. Miyauchi A, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, et al. 3,5,3′-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma. J Clin Endocrinol Metab. 2008 Jun;93(6):2239-42.
  31. Takano T, Miyauchi A, Ito Y, Amino N. Thyroxine to triiodothyronine hyperconversion thyrotoxicosis in patients with large metastases of follicular thyroid carcinoma. Thyroid. 2006 Jun;16(6):615-8.
  32. Schneider MJ, Fiering SN, Pallud SE, Parlow AF, St Germain DL, Galton VA. Targeted disruption of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of pituitary resistance to T4. Mol Endocrinol. 2001 Dec;15(12):2137-48.
  33. Marsili A, Ramadan W, Harney JW, Mulcahey M, Castroneves LA, Goemann IM, et al. Type 2 iodothyronine deiodinase levels are higher in slow-twitch than fast-twitch mouse skeletal muscle and are increased in hypothyroidism. Endocrinology. 2010 Dec;151(12):5952-60.
  34. Werneck-de-Castro JP, Fonseca TL, Ignacio DL, Fernandes GW, Andrade-Feraud CM, Lartey LJ et al. Thyroid hormone signaling in male mouse skeletal muscle is largely independent of D2 in myocytes. Endocrinology. 2015 Oct;156(10):3842-52.
  35. Ignacio DL, Silvestre DH, Palmer E, Bocco B, Fonseca T, Gereben B et al. Early developmental disruption of type 2 deiodinase pathway in mouse skeletal muscle does not impair muscle function. Thyroid. 2016 Dec 14. [Epub ahead of print]
  36. Campos-Barros A, Amma LL, Faris JS, Shailam R, Kelley MW, Forrest D. Type 2 iodothyronine deiodinase expression in the cochlea before the onset of hearing. Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1287-92.
  37. Ng L, Goodyear RJ, Woods CA, Schneider MJ, Diamond E, Richardson GP, et al. Hearing loss and retarded cochlear development in mice lacking type 2 iodothyronine deiodinase. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3474-9.
  38. Hall JA, Ribich S, Christoffolete MA, Simovic G, Correa-Medina M, Patti ME, et al. Absence of thyroid hormone activation during development underlies a permanent defect in adaptive thermogenesis. Endocrinology. 2010 Sep;151(9):4573-82.
  39. de Jesus LA, Carvalho SD, Ribeiro MO, Schneider M, Kim SW, Harney JW, et al. The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. J Clin Invest. 2001 Nov;108(9):1379-85.
  40. Castillo M, Hall JA, Correa-Medina M, Ueta C, Kang HW, Cohen DE, et al. Disruption of thyroid hormone activation in type 2 deiodinase knockout mice causes obesity with glucose intolerance and liver steatosis only at thermoneutrality. Diabetes. 2011 Apr;60(4):1082-9.
  41. Bocco BM, Werneck-de-Castro JP, Oliveira KC, Fernandes GW, Fonseca TL, Nascimento BP et al. Type 2 deiodinase disruption in astrocytes results in anxiety-depressive-like behavior in male mice. Endocrinology. 2016 Sep;157(9):3682-95.
  42. Dentice M, Marsili A, Ambrosio R, Guardiola O, Sibilio A, Paik JH, et al. The FoxO3/type 2 deiodinase pathway is required for normal mouse myogenesis and muscle regeneration. J Clin Invest. 2010 Nov;120(11):4021-30.
  43. Bassett JH, Boyde A, Howell PG, Bassett RH, Galliford TM, Archanco M, et al. Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. Proc Natl Acad Sci U S A. Apr 20;107(16):7604-9.
  44. Kwakkel J, van Beeren HC, Ackermans MT, Platvoet-Ter Schiphorst MC, Fliers E, Wiersinga WM, et al. Skeletal muscle deiodinase type 2 regulation during illness in mice. J Endocrinol. 2009 Nov;203(2):263-70.
  45. Heemstra KA, Soeters MR, Fliers E, Serlie MJ, Burggraaf J, van Doorn MB, et al. Type 2 iodothyronine deiodinase in skeletal muscle: effects of hypothyroidism and fasting. J Clin Endocrinol Metab. 2009 Jun;94(6):2144-50.
  46. Barca-Mayo O, Liao XH, DiCosmo C, Dumitrescu A, Moreno-Vinasco L, Wade MS, et al. Role of type 2 deiodinase in response to acute lung injury (ALI) in mice. Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):E1321-9.
  47. Schoenmakers E, Agostini M, Mitchell C, Schoenmakers N, Papp L, Rajanayagam O, et al. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. J Clin Invest. 2010 Dec;120(12):4220-35.
  48. Dumitrescu AM, Liao XH, Abdullah MS, Lado-Abeal J, Majed FA, Moeller LC, et al. Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. Nat Genet. 2005 Nov;37(11):1247-52.
  49. Canani LH, Capp C, Dora JM, Meyer EL, Wagner MS, Harney JW, et al. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2005 Jun;90(6):3472-8.
  50. Grarup N, Andersen MK, Andreasen CH, Albrechtsen A, Borch-Johnsen K, Jorgensen T, et al. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. J Clin Endocrinol Metab. 2007 Jan;92(1):363-6.
  51. Peeters RP, van den Beld AW, Attalki H, Toor H, de Rijke YB, Kuiper GG, et al. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. Am J Physiol Endocrinol Metab. 2005 Jul;289(1):E75-81.
  52. Peeters RP, van Toor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG, et al. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab. 2003 Jun;88(6):2880-8.
  53. Meulenbelt I, Min JL, Bos S, Riyazi N, Houwing-Duistermaat JJ, van der Wijk HJ, et al. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. Hum Mol Genet. 2008 Jun 15;17(12):1867-75.
  54. Bates JM, St Germain DL, Galton VA. Expression profiles of the three iodothyronine deiodinases, D1, D2, and D3, in the developing rat. Endocrinology. 1999 Feb;140(2):844-51.
  55. Galton VA, Martinez E, Hernandez A, St Germain EA, Bates JM, St Germain DL. Pregnant rat uterus expresses high levels of the type 3 iodothyronine deiodinase. J Clin Invest. 1999 Apr;103(7):979-87.
  56. Santini F, Vitti P, Chiovato L, Ceccarini G, Macchia M, Montanelli L, et al. Role for inner ring deiodination preventing transcutaneous passage of thyroxine. J Clin Endocrinol Metab. 2003 Jun;88(6):2825-30.
  57. Dentice M, Luongo C, Huang S, Ambrosio R, Elefante A, Mirebeau-Prunier D, et al. Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes. Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14466-71.
  58. Huang SA, Dorfman DM, Genest DR, Salvatore D, Larsen PR. Type 3 iodothyronine deiodinase is highly expressed in the human uteroplacental unit and in fetal epithelium. J Clin Endocrinol Metab. 2003 Mar;88(3):1384-8.
  59. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med. 2000 Jul 20;343(3):185-9.
  60. Sato K, Robbins J. Thyroid hormone metabolism in cultured monkey hepatocarcinoma cells. Monodeiodination activity in relation to cell growth. J Biol Chem. 1980 Aug 10;255(15):7347-52.
  61. Baqui M, Botero D, Gereben B, Curcio C, Harney JW, Salvatore D, et al. Human type 3 iodothyronine selenodeiodinase is located in the plasma membrane and undergoes rapid internalization to endosomes. J Biol Chem. 2003 Jan 10;278(2):1206-11.
  62. Sagar GD, Gereben B, Callebaut I, Mornon JP, Zeold A, Curcio-Morelli C, et al. The thyroid hormone-inactivating deiodinase functions as a homodimer. Mol Endocrinol. 2008 Jun;22(6):1382-93.
  63. Tu HM, Legradi G, Bartha T, Salvatore D, Lechan RM, Larsen PR. Regional expression of the type 3 iodothyronine deiodinase messenger ribonucleic acid in the rat central nervous system and its regulation by thyroid hormone. Endocrinology. 1999 Feb;140(2):784-90.
  64. Barca-Mayo O, Liao XH, Alonso M, Di Cosmo C, Hernandez A, Refetoff S, et al. Thyroid hormone receptor alpha and regulation of type 3 deiodinase. Mol Endocrinol. 2011 Apr;25(4):575-83.
  65. Macchia PE, Takeuchi Y, Kawai T, Cua K, Gauthier K, Chassande O, et al. Increased sensitivity to thyroid hormone in mice with complete deficiency of thyroid hormone receptor alpha. Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):349-54.
  66. Kester MH, Martinez de Mena R, Obregon MJ, Marinkovic D, Howatson A, Visser TJ, et al. Iodothyronine levels in the human developing brain: major regulatory roles of iodothyronine deiodinases in different areas. J Clin Endocrinol Metab. 2004 Jul;89(7):3117-28.
  67. Santini F, Pinchera A, Ceccarini G, Castagna M, Rosellini V, Mammoli C, et al. Evidence for a role of the type III-iodothyronine deiodinase in the regulation of 3,5,3′-triiodothyronine content in the human central nervous system. Eur J Endocrinol. 2001 Jun;144(6):577-83.
  68. Huang SA, Fish SA, Dorfman DM, Salvatore D, Kozakewich HP, Mandel SJ, et al. A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase. J Clin Endocrinol Metab. 2002 Oct;87(10):4457-61.
  69. Peeters RP, van der Geyten S, Wouters PJ, Darras VM, van Toor H, Kaptein E, et al. Tissue thyroid hormone levels in critical illness. J Clin Endocrinol Metab. 2005 Dec;90(12):6498-507.
  70. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab. 2003 Jul;88(7):3202-11.
  71. Peeters RP, Wouters PJ, van Toor H, Kaptein E, Visser TJ, Van den Berghe G. Serum 3,3′,5′-triiodothyronine (rT3) and 3,5,3′-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab. 2005 Aug;90(8):4559-65.
  72. Hernandez A, Fiering S, Martinez E, Galton VA, St Germain D. The gene locus encoding iodothyronine deiodinase type 3 (Dio3) is imprinted in the fetus and expresses antisense transcripts. Endocrinology. 2002 Nov;143(11):4483-6.
  73. Hernandez A, Martinez ME, Fiering S, Galton VA, St Germain D. Type 3 deiodinase is critical for the maturation and function of the thyroid axis. J Clin Invest. 2006 Feb;116(2):476-84.
  74. Hernandez A, Martinez ME, Liao XH, Van Sande J, Refetoff S, Galton VA, et al. Type 3 deiodinase deficiency results in functional abnormalities at multiple levels of the thyroid axis. Endocrinology. 2007 Dec;148(12):5680-7.
  75. Kempers MJ, van Tijn DA, van Trotsenburg AS, de Vijlder JJ, Wiedijk BM, Vulsma T. Central congenital hypothyroidism due to gestational hyperthyroidism: detection where prevention failed. J Clin Endocrinol Metab. 2003 Dec;88(12):5851-7.
  76. Hernandez A, Garcia B, Obregon MJ. Gene expression from the imprinted Dio3 locus is associated with cell proliferation of cultured brown adipocytes. Endocrinology. 2007 Aug;148(8):3968-76.
  77. Charalambous M, Ferron SR, da Rocha ST, Murray AJ, Rowland T, Ito M, et al. Imprinted gene dosage is critical for the transition to independent life. Cell Metab. 2012 Feb 8;15(2):209-21.
  78. Van der Geyten S, Buys N, Sanders JP, Decuypere E, Visser TJ, Kuhn ER, et al. Acute pretranslational regulation of type III iodothyronine deiodinase by growth hormone and dexamethasone in chicken embryos. Mol Cell Endocrinol. 1999 Jan 25;147(1-2):49-56.
  79. Van der Geyten S, Sanders JP, Kaptein E, Darras VM, Kuhn ER, Leonard JL, et al. Expression of chicken hepatic type I and type III iodothyronine deiodinases during embryonic development. Endocrinology. 1997 Dec;138(12):5144-52.
  80. Richard K, Hume R, Kaptein E, Sanders JP, van Toor H, De Herder WW, et al. Ontogeny of iodothyronine deiodinases in human liver. J Clin Endocrinol Metab. 1998 Aug;83(8):2868-74.
  81. Koopdonk-Kool JM, de Vijlder JJ, Veenboer GJ, Ris-Stalpers C, Kok JH, Vulsma T, et al. Type II and type III deiodinase activity in human placenta as a function of gestational age. J Clin Endocrinol Metab. 1996 Jun;81(6):2154-8.
  82. Roti E, Gnudi A, Braverman LE. The placental transport, synthesis and metabolism of hormones and drugs which affect thyroid function. Endocr Rev. 1983 Spring;4(2):131-49.
  83. Ng L, Hernandez A, He W, Ren T, Srinivas M, Ma M, et al. A protective role for type 3 deiodinase, a thyroid hormone-inactivating enzyme, in cochlear development and auditory function. Endocrinology. 2009 Apr;150(4):1952-60.
  84. Peeters RP, Hernandez A, Ng L, Ma M, Sharlin DS, Pandey M, et al. Cerebellar Abnormalities in Mice Lacking Type 3 Deiodinase and Partial Reversal of Phenotype by Deletion of Thyroid Hormone Receptor alpha1. Endocrinology. 2012 Nov 16.
  85. Ng L, Lyubarsky A, Nikonov SS, Ma M, Srinivas M, Kefas B, et al. Type 3 deiodinase, a thyroid-hormone-inactivating enzyme, controls survival and maturation of cone photoreceptors. J Neurosci. 2010 Mar 3;30(9):3347-57.
  86. Medina MC, Molina J, Gadea Y, Fachado A, Murillo M, Simovic G, et al. The thyroid hormone-inactivating type III deiodinase is expressed in mouse and human beta-cells and its targeted inactivation impairs insulin secretion. Endocrinology. 2011 Oct;152(10):3717-27.
  87. Olivares EL, Marassi MP, Fortunato RS, da Silva AC, Costa-e-Sousa RH, Araujo IG, et al. Thyroid function disturbance and type 3 iodothyronine deiodinase induction after myocardial infarction in rats a time course study. Endocrinology. 2007 Oct;148(10):4786-92.
  88. Simonides WS, Mulcahey MA, Redout EM, Muller A, Zuidwijk MJ, Visser TJ, et al. Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. J Clin Invest. 2008 Mar;118(3):975-83.
  89. Wassen FW, Schiel AE, Kuiper GG, Kaptein E, Bakker O, Visser TJ, et al. Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology. 2002 Jul;143(7):2812-5.
  90. Jo S, Kallo I, Bardoczi Z, Arrojo e Drigo R, Zeold A, Liposits Z, et al. Neuronal hypoxia induces Hsp40-mediated nuclear import of type 3 deiodinase as an adaptive mechanism to reduce cellular metabolism. J Neurosci. 2012 Jun 20;32(25):8491-500.
  91. Ueta CB, Oskouei BN, Olivares EL, Pinto JR, Correa MM, Simovic G, et al. Absence of myocardial thyroid hormone inactivating deiodinase results in restrictive cardiomyopathy in mice. Mol Endocrinol. 2012 May;26(5):809-18.
  92. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. Endocr Rev. 2011 Oct;32(5):670-93.
  93. Boelen A, Kwakkel J, Alkemade A, Renckens R, Kaptein E, Kuiper G, et al. Induction of type 3 deiodinase activity in inflammatory cells of mice with chronic local inflammation. Endocrinology. 2005 Dec;146(12):5128-34.
  94. Boelen A, Boorsma J, Kwakkel J, Wieland CW, Renckens R, Visser TJ, et al. Type 3 deiodinase is highly expressed in infiltrating neutrophilic granulocytes in response to acute bacterial infection. Thyroid. 2008 Oct;18(10):1095-103.
  95. Kester MH, Toussaint MJ, Punt CA, Matondo R, Aarnio AM, Darras VM, et al. Large induction of type III deiodinase expression after partial hepatectomy in the regenerating mouse and rat liver. Endocrinology. 2009 Jan;150(1):540-5.
  96. Li WW, Le Goascogne C, Ramauge M, Schumacher M, Pierre M, Courtin F. Induction of type 3 iodothyronine deiodinase by nerve injury in the rat peripheral nervous system. Endocrinology. 2001 Dec;142(12):5190-7.
  97. Dentice M, Salvatore D. Deiodinases: the balance of thyroid hormone: local impact of thyroid hormone inactivation. J Endocrinol. 2011 Jun;209(3):273-82.
  98. Tanimizu N, Miyajima A. Molecular mechanism of liver development and regeneration. Int Rev Cytol. 2007;259:1-48.
  99. Kester MH, Kuiper GG, Versteeg R, Visser TJ. Regulation of type III iodothyronine deiodinase expression in human cell lines. Endocrinology. 2006 Dec;147(12):5845-54.
  100. Romitti M, Wajner SM, Zennig N, Goemann IM, Bueno AL, Meyer EL, et al. Increased type 3 deiodinase expression in papillary thyroid carcinoma. Thyroid. 2012 Sep;22(9):897-904.
  101. Pacifici GM, Coughtrie MW. Human Cytosolic Sulfotransferases. Baco Raton: Taylor & Francis; 2005.
  102. Blanchard RL, Freimuth RR, Buck J, Weinshilboum RM, Coughtrie MW. A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily. Pharmacogenetics. 2004 Mar;14(3):199-211.
  103. Fujita K, Nagata K, Ozawa S, Sasano H, Yamazoe Y. Molecular cloning and characterization of rat ST1B1 and human ST1B2 cDNAs, encoding thyroid hormone sulfotransferases. J Biochem. 1997 Nov;122(5):1052-61.
  104. Kester MH, Kaptein E, Roest TJ, van Dijk CH, Tibboel D, Meinl W, et al. Characterization of human iodothyronine sulfotransferases. J Clin Endocrinol Metab. 1999 Apr;84(4):1357-64.
  105. Kester MH, van Dijk CH, Tibboel D, Hood AM, Rose NJ, Meinl W, et al. Sulfation of thyroid hormone by estrogen sulfotransferase. J Clin Endocrinol Metab. 1999 Jul;84(7):2577-80.
  106. Li X, Anderson RJ. Sulfation of iodothyronines by recombinant human liver steroid sulfotransferases. Biochem Biophys Res Commun. 1999 Oct 5;263(3):632-9.
  107. Li X, Clemens DL, Anderson RJ. Sulfation of iodothyronines by human sulfotransferase 1C1 (SULT1C1)*. Biochem Pharmacol. 2000 Dec 1;60(11):1713-6.
  108. Pietsch CA, Scanlan TS, Anderson RJ. Thyronamines are substrates for human liver sulfotransferases. Endocrinology. 2007 Apr;148(4):1921-7.
  109. Visser TJ, Kaptein E, Glatt H, Bartsch I, Hagen M, Coughtrie MW. Characterization of thyroid hormone sulfotransferases. Chem Biol Interact. 1998 Feb 20;109(1-3):279-91.
  110. Wang J, Falany JL, Falany CN. Expression and characterization of a novel thyroid hormone-sulfating form of cytosolic sulfotransferase from human liver. Mol Pharmacol. 1998 Feb;53(2):274-82.
  111. Venkatachalam KV, Akita H, Strott CA. Molecular cloning, expression, and characterization of human bifunctional 3′-phosphoadenosine 5′-phosphosulfate synthase and its functional domains. J Biol Chem. 1998 Jul 24;273(30):19311-20.
  112. Eelkman Rooda SJ, Kaptein E, Visser TJ. Serum triiodothyronine sulfate in man measured by radioimmunoassay. J Clin Endocrinol Metab. 1989 Sep;69(3):552-6.
  113. Chopra MFI. Nonthyroidal illness syndrome or euthyroid sick syndrome? Endocr Pract. 1996;2(1):45-52.
  114. Chopra IJ, Nguyen D. Demonstration of thyromimetic effects of 3,5,3′-triiodothyronine sulfate (T3S) in euthyroid rats. Thyroid. 1996 Jun;6(3):229-32.
  115. Kester MH, Kaptein E, Van Dijk CH, Roest TJ, Tibboel D, Coughtrie MW, et al. Characterization of iodothyronine sulfatase activities in human and rat liver and placenta. Endocrinology. 2002 Mar;143(3):814-9.
  116. Santini F, Chopra IJ, Wu SY, Solomon DH, Chua Teco GN. Metabolism of 3,5,3′-triiodothyronine sulfate by tissues of the fetal rat: a consideration of the role of desulfation of 3,5,3′-triiodothyronine sulfate as a source of T3. Pediatr Res. 1992 Jun;31(6):541-4.
  117. Wu SY, Huang WS, Ho E, Wu ES, Fisher DA. Compound W, a 3,3′-diiodothyronine sulfate cross-reactive substance in serum from pregnant women–a potential marker for fetal thyroid function. Pediatr Res. 2007 Mar;61(3):307-12.
  118. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics. 2005 Oct;15(10):677-85.
  119. Hennemann G, Visser TJ. Thyroid hormone synthesis, plasma membrane transport, and metabolism.1997.
  120. Brouwer A, Morse DC, Lans MC, Schuur AG, Murk AJ, Klasson-Wehler E, et al. Interactions of persistent environmental organohalogens with the thyroid hormone system: mechanisms and possible consequences for animal and human health. Toxicol Ind Health. 1998 Jan-Apr;14(1-2):59-84.
  121. Klaassen CD, Hood AM. Effects of microsomal enzyme inducers on thyroid follicular cell proliferation and thyroid hormone metabolism. Toxicol Pathol. 2001 Jan-Feb;29(1):34-40.
  122. Visser TJ, Kaptein E, van Toor H, van Raaij JA, van den Berg KJ, Joe CT, et al. Glucuronidation of thyroid hormone in rat liver: effects of in vivo treatment with microsomal enzyme inducers and in vitro assay conditions. Endocrinology. 1993 Nov;133(5):2177-86.
  123. Benedetti MS, Whomsley R, Baltes E, Tonner F. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. Eur J Clin Pharmacol. 2005 Dec;61(12):863-72.
  124. Kato Y, Ikushiro S, Emi Y, Tamaki S, Suzuki H, Sakaki T, et al. Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans. Drug Metab Dispos. 2008 Jan;36(1):51-5.
  125. Tong Z, Li H, Goljer I, McConnell O, Chandrasekaran A. In vitro glucuronidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2007 Dec;35(12):2203-10.
  126. Yamanaka H, Nakajima M, Katoh M, Yokoi T. Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. Drug Metab Dispos. 2007 Sep;35(9):1642-8.
  127. Yoder Graber AL, Ramirez J, Innocenti F, Ratain MJ. UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics. 2007 Aug;17(8):619-27.
  128. Moreno M, Kaptein E, Goglia F, Visser TJ. Rapid glucuronidation of tri- and tetraiodothyroacetic acid to ester glucuronides in human liver and to ether glucuronides in rat liver. Endocrinology. 1994 Sep;135(3):1004-9.
  129. Bernal J. Thyroid hormone receptors in brain development and function. Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):249-59.
  130. Bernal J. Thyroid hormone transport in developing brain. Curr Opin Endocrinol Diabetes Obes. 2011 Oct;18(5):295-9.
  131. Heuer H, Maier MK, Iden S, Mittag J, Friesema EC, Visser TJ, et al. The monocarboxylate transporter 8 linked to human psychomotor retardation is highly expressed in thyroid hormone-sensitive neuron populations. Endocrinology. 2005 Apr;146(4):1701-6.
  132. Fonseca TL, Fernandes GW, McAninch EA, Bocco BM, Abdalla SM, Ribeiro MO et al. Perinatal deiodinase 2 expression in hepatocytes defines epigenetic susceptibility to liver steatosis and obesity. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):14018-23.
  133. Huang SA. Deiodination and cellular proliferation: parallels between development, differentiation, tumorigenesis, and now regeneration. Endocrinology. 2009 Jan;150(1):3-4.
  134. Wittmann G, Harney JW, Singru PS, Nouriel SS, Reed Larsen P, Lechan RM. Inflammation-inducible type 2 deiodinase expression in the leptomeninges, choroid plexus, and at brain blood vessels in male rodents. Endocrinology. 2014 May;155(5):2009-19.
  135. Kwakkel J, Surovtseva OV, de Vries EM, Stap J, Fliers E, Boelen A. A novel role for the thyroid hormone-activating enzyme type 2 deiodinase in the inflammatory response of macrophages. Endocrinology. 2014;155:2725–2734.
  136. Medici M, Visser WE, Visser TJ, Peeters RP. Genetic determination of the hypothalamic-pituitary-thyroid axis: where do we stand? Endocr Rev. 2015 Apr;36(2):214-44.
  137. Zevenbergen C, Klootwijk W, Peeters RP, Medici M, de Rijke YB, Huisman SA, et al. Functional analysis of novel genetic variation in the thyroid hormone activating type 2 deiodinase.

J Clin Endocrinol Metab. 2014 Nov;99(11):E2429-36.

  1. McAninch EA, Jo S, Preite NZ, Farkas E, Mohácsik P, Fekete C, Egri P et al. Prevalent polymorphism in thyroid hormone-activating enzyme leaves a genetic fingerprint that underlies associated clinical syndromes. J Clin Endocrinol Metab. 2015 Mar;100(3):920-33.
  2. Maynard MA, Marino-Enriquez A, Fletcher JA, Dorfman DM, Raut CP, Yassa L et al. Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med. 2014 Apr 3;370(14):1327-34
  3. Schweizer U, Schlicker C, Braun D, Köhrle J, Steegborn C5. Crystal structure of mammalian selenocysteine-dependent iodothyronine deiodinase suggests a peroxiredoxin-like catalytic mechanism. Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10526-31.
  4. Martinez ME, Charalambous M, Saferali A, Fiering S, Naumova AK, St Germain D et al. Genomic imprinting variations in the mouse type 3 deiodinase gene between tissues and brain regions. Mol Endocrinol. 2014 Nov;28(11):1875-86.
  5. Medina MC, Fonesca TL, Molina J, Fachado A, Castillo M, Dong L et al. Maternal inheritance of an inactive type III deiodinase gene allele affects mouse pancreatic β-cells and disrupts glucose homeostasis. Endocrinology. 2014 Aug;155(8):3160-71.
  6. Stohn JP, Martinez ME, Hernandez A. Decreased anxiety- and depression-like behaviors and hyperactivity in a type 3 deiodinase-deficient mouse showing brain thyrotoxicosis and peripheral hypothyroidism. Psychoneuroendocrinology. 2016 Aug 24;74:46-56.
  7. Stohn JP, Martinez ME, Matoin K, Morte B, Bernal J, Galton VA et al. Mct8 deficiency in male mice mitigates the phenotypic abnormalities associated with the absence of a functional type 3 deiodinase. Endocrinology. 2016 Aug;157(8):3266-77.
  8. Houbrechts AM, Vergauwen L, Bagci E, Van Houcke J, Heijlen M, Kulemeka B et al. Deiodinase knockdown affects zebrafish eye development at the level of gene expression, morphology and function. Mol Cell Endocrinol. 2016 Mar 15;424:81-93.
  9. Martinez ME, Karaczyn A, Stohn JP, Donnelly WT, Croteau W, Peeters RP et al. The type 3 deiodinase is a critical determinant of appropriate thyroid hormone action in the developing testis. Endocrinology. 2016 Mar;157(3):1276-88.
  10. Wu Z, Martinez ME, St Germain DL, Hernandez A. Type 3 deiodinase role on central thyroid hormone action affects the leptin-melanocortin system and circadian activity. Endocrinology. 2016 Dec 2:en20161680. [Epub ahead of print]
  11. Van der Spek AH, Bloise FF, Tigchelaar W, Dentice M, Salvatore D, van der Wel NN et al. The Thyroid Hormone Inactivating Enzyme Type 3 Deiodinase is Present in Bactericidal Granules and the Cytoplasm of Human Neutrophils. Endocrinology. 2016 Aug;157(8):3293-305.
  12. Visser WE, Bombardieri CR, Zevenbergen C, Barnhoorn S, Ottaviani A, van der Pluijm I et al. Tissue-specific suppression of thyroid hormone signaling in various mouse models of aging. PLoS One. 2016 Mar 8;11(3):e0149941.
  13. Dentice M, Ambrosio R, Damiano V, Sibilio A, Luongo C, Guardiola O et al. Intracellular inactivation of thyroid hormone is a survival mechanism for muscle stem cell proliferation and lineage progression. Cell Metab. 2014 Dec 2;20(6):1038-48.
  14. Luongo C, Ambrosio R, Salzano S, Dlugosz AA, Missero C, Dentice M. The sonic hedgehog-induced type 3 deiodinase facilitates tumorigenesis of basal cell carcinoma by reducing Gli2 inactivation. Endocrinology. 2014 Jun;155(6):2077-88.
  15. Di Girolamo D, Ambrosio R, De Stefano MA, Mancino G, Porcelli T, Luongo C et al. Reciprocal interplay between thyroid hormone and microRNA-21 regulates hedgehog pathway–driven skin tumorigenesis. J Clin Invest. 2016 Jun 1; 126(6): 2308–2320.
  16. Galton VA, de Waard E, Parlow AF, St Germain DL, Hernandez A. Life without the iodothyronine deiodinases. Endocrinology. 2014 Oct;155(10):4081-7.